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4.1   Introduction 
-Mannosyl phosphomycoketides (MPM’s) 4.1 and 4.2 are unusual mycobacterial 
antigens that were recently isolated in minute amounts by Moody and co-workers1 from the 
cell wall of Mycobacterium tuberculosis and Mycobacterium avium, respectively (Figure 
4.1). Initial structural characterization was based on degradation and mass spectrometric 
studies and did not include elucidation of the stereochemistry of the oligoisoprenoid chain.1 
In 2002, Dudkin and Crich reported the synthesis of 4.2, confirming the overall molecular 
structure.2 However, as a stereorandom alkyl chain (mixture of 32 diastereoisomers) was 
used, the stereochemistry of the lipid part remained unsolved. 
4.1 R = n-C7H15
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Figure 4.1 Molecular structure of -mannosyl phosphomycoketides. 
Structurally, 4.1 and 4.2 resemble a partially saturated -mannosyl heptaprenyl 
phosphate isolated from M. smegmatis (Figure 4.2), that serves as a carrier of mycolic 
acid.3 However, an important difference from a biological point of view is that 4.1 and 4.2 
violate the isoprene rule at both ends of their alkyl chain, which has implications for the 
biosynthetic pathway by which these saturated isoprenoid chains are assembled (see § 4.4). 
From our perspective, 4.1 constituted a challenge to apply our procedure for the 
preparation of enantiopure saturated isoprenoid building blocks (Chapter 3) to a more 
complex target. Hence, we aimed to develop a general protocol for the construction of 


























Figure 4.2 Related -mannosyl heptaprenyl phosphate isolated from M. Smegmatis.3 
4.2   Lipid-antigen mediated immune response 
The success of the (human) immune system depends on its ability to distinguish foreign 
antigens from self-elements and to initiate appropriate effector mechanisms that destroy 
alien intruders without inflicting damage to self-elements.4 The mammalian immune system 
utilizes two major recognition strategies: innative and adaptive. Innate immune responses 
use pattern-recognition receptors such as lectins and the Toll-like receptors to recognize 
specific foreign molecules that are characteristic for microbial species. By focusing on 
conserved structural motifs that are common among pathogens, the innate immune system 
is able to respond immediately in case of infection. In contrast, the adaptive immune system 
uses recombinatorial antigen-receptors and is therefore able to interact with an almost 
infinite number of structures, although its response is generally slower. The main mediators 
of adaptive immune responses are T and B lymphocytes. While B-cells produce antibodies 
that can interact with epitopes of any molecular species, T-cells were believed until recently 
to be activated exclusively by peptides which are presented by major histocompatibility 
(MHC) class I and II proteins.5 In 1992, though, Porcelli et al. showed that a second class 
of antigen presenting proteins, known as the Cluster of Differentiation 1 (CD1) family, is 
capable of inducing proliferation of T-cells which are specific for microbial pathogens.6 
Two years later they disclosed, that CD1 molecules have in fact the ability to present lipid 
antigens rather than peptides.7 Finally, in 2000, Moody et al. provided strong evidence that 
CD1-lipid complexes indeed play an important role in resistance to microbial infections in 
vivo via activation of T-cells.1,8 Since then, four members of the CD1 family (CD1a to 
CD1d) have been proven to present at least five classes of (glyco)lipids:9 mycolates,7 
glycosphinglolipids,10 phospholipids,11 sulfoglycolipids12 and lipopeptides.13 Based on 
  
 







sequence similarities, the CD1 isoforms have been divided in two groups: CD1a, b, and c 
(group 1) and CD1d (group 2). The fact that many CD1d restricted T-cells express a semi-
invariant T-cell antigen receptor (TCR) suggests that they may function as a pattern-
recognition receptor of the innate immune system, while CD1a, b and c are part of the 
adaptive immune system.5 
From a chemical point of view, lipids seem to be an unlikely target for recognition by T-
cells. They are insoluble in the aqueous environment in which antigen-presenting molecules 
and T-cells function. Moreover, the high degree of conformational freedom of a long 
aliphatic chain and the absence of functional groups for hydrogen bonding, makes specific 
interactions with T-cell receptors (TCRs) unlikely. This paradox was partly resolved, when 
crystal structures of CD1 proteins showed the presence of large hydrophobic cavities.14 
Based on these crystal structures and on investigations to establish the molecular 
determinants for antigen recognition,15 a model was proposed in which van der Waals 
interactions are maximized by embedding of the aliphatic chain(s) into the hydrophobic 
groove, while the polar headgroup is presented at the surface to interact with the TCR 



















4.2.1   CD1 proteins and lipid antigen presentation 
Considering the limited -amino acid sequence homology (< 36%) between CD1 
proteins and MHC class I proteins, their three-dimensional structures are remarkably 
similar. Both antigen presenting molecules are integral membrane glycoproteins containing 
three domains (1, 2 and 3), that form non-covalent heterodimers with 2-microglobulin 
(Figure 4.3).4 When evaluating tissue expression, CD1 proteins are more reminiscent of 
MHC class II proteins, in that they are mainly present on specialized antigen-presenting 
cells (APC’s) like B cells, macrophages and dendritic cells. However, unlike MHC class I 
and class II proteins, human CD1 proteins are nonpolymorphic so that genetically unrelated 
individuals express nearly identical CD1 gene products. It is speculated that the overall lack 
of polymorphism of CD1 alleles is related to the limited structural variation in lipid tails of 
microbial species. In contrast to proteins, lipids and glycolipids are products of multi-
enzyme biosynthetic pathways and their structures are therefore highly conserved.4,16 
Moreover, (glyco)lipids are responsible for the integrity of the mycobacterial cell envelope, 
so that small changes in their structure are often detrimental for the survival of the 
bacterium.17 Incidentally, this conservation of structure makes these non-mammalian 
(glyco)lipids interesting biological targets for both drugs (such as isoniazid) and vaccines. 
CD1 molecules are synthesized in the endoplasmic reticulum (ER), where N-linked 
glycans are attached and association with 2-microglobulin occurs.18 ER chaperones and 
self lipids subsequently assist proper folding,19 after which the CD1 complex is transported 
from the Golgi apparatus to the plasma membrane, presumably along the secretory pathway 
(Figure 4.4).20 Surface CD1 proteins are then internalized, in case of CD1b and CD1c 
through the interaction of a tyrosine-motif in the cytoplasmic domain with adaptor protein 
complex 2 (AP2). Specific CD1 molecules are transported to particular intracellular 
compartments where the previously bound self lipids are exchanged for distinct foreign- or 
other self lipids. CD1a is predominantly targeted to recycling endosomes, CD1b is sorted to 
late endosomes and lysosomes, CD1c broadly traffics to all compartments and CD1d is 
found mainly in early and late endosomes. 
The transport of lipids from hydrophobic environments like membranes and CD1 
grooves to the aqueous lumens of intracellular compartments is a thermodynamically 
unfavorable process. Recent studies on the regulation of antigen presentation by human 
  
 







CD1b and CD1d show that the loading of lipids is assisted by sphinglolipid activator 
proteins (SAP), presumably through their interaction with the polar heads of lipids.9,21 The 
pathways that direct the CD1 molecules from the internal compartments back to the plasma 
membrane have not been elucidated yet. 
 
 Figure 4.4 Intracellular trafficking and loading of CD1c and CD1d  molecules.16 
4.2.2   Recognition of CD1-lipid complexes by T-cell antigen receptors 
T-cell antigen receptors (TCRs) that recognize peptide antigens bound in the groove of 
MHC molecules are heterodimers consisting of an  and a  chain. The specific interaction 
is mediated by the complementarity-determining residue (CDR) loops of the  and  chains 
which contact exposed residues of the peptide antigen and -amino acids along the MHC  
helices. The three-dimensional resemblance of CD1 molecules to MHC class I proteins (§ 
4.2.1) allows the same type of / TCR heterodimers to specifically interact with CD1-lipid 
complexes as well. Indeed, the primary structure of TCRs that recognize CD1a, b and c in 
the presence of lipid antigens are indistinguishable from those that recognize MHC class I 
or II complexes with peptides.22 
In general, TCRs are highly specific for the epitope that is formed by the combination of 
a particular CD1 family member and a certain lipid antigen, even though there are some 
reports of self-recognition of CD1 in the absence of an antigen.23 The molecular basis of the 
























CD1-lipid-TCR interaction awaits the determination of the structure of the tri-molecular 
complex (Figure 4.3). Frequent usage of basic -amino acids in the CDR regions of the 
TCR suggests a model in which these CDR loops project directly between the CD1  
helices to participate in electrostatic interactions with the polar headgroups of the lipid 
antigens.22 In concurrence with this model, TCRs can distinguish even small changes in the 
structure of the hydrophilic headgroup of antigens,7,15,24,25 while alterations in the aliphatic 
tail often have less pronounced effects. Nevertheless, the influence of the aliphatic tail 
cannot be dismissed as inconsequential, since it often provides the (only) principal basis for 
discrimination of self- and non-self structures.26 
4.2.3   Effector functions of T-cells 
In the peptide mediated system, class I MHC-peptide complexes can be found at the 
surface of infected cells, where they specifically bind to cytolytic T-cells having a 
CD8+TCR. Upon recognition, the cytolytic T-cells initiate an immune response which 
eventually leads to the lysis of the infected cells as well as killing of the invading pathogen. 
Class II MHC-peptide complexes on the other hand are presented at the surface of B cells, 
macrophages and dendritic cells where they specifically interact with T-helper cells 
(Th1/Th2) having a CD4+TCR. In this case, recognition results in the secretion of a variety 
of cytokines which stimulate the maturation, proliferation and activation of a range of 
different T-cells, B-cells, macrophages and so on. De facto, a cell is either killed or 
proliferated depending on the presented MHC-peptide complex and a strict separation of 
these activities is obviously instrumental for the proper functioning of the immune system.  
In this light, it is noteworthy, that group 1 CD1-lipid complexes are recognized by both 
T-cells expressing a CD8+TCR as well as by T-cells having a CD4+TCR among others. To 
make the situation even more complex, some CD1-restricted T-cells display both effector 
functions characteristic for cytolytic T-cells as well as features of T-helper cells.5 Indeed, 
the same CD1-restricted T-cell that is involved in the lysis of infected cells and in direct 
antimicrobial activity via the secretion of perforin and granulysin, respectively,27 can also 
be responsible for the production of interferon- (IFN-) and tumor necrosis factor- (TNF-
), which activate the microbicidal functions of macrophages (Figure 4.5).5,16 How the 
lipid-based immune system distinguishes infected cells, which have to be lysed, from B 
  
 







cells, macrophages and dendritic cells, which have to be proliferated, remains to be 
elucidated. 
 
Figure 4.5 Effector functions of CD1-restricted T cells.16 
4.2.4   Rationale for a lipid-antigen mediated immune response 
The rationale for a lipid-antigen mediated immune response is still a subject of debate. It 
may be that the lipid-antigen mediated pathway serves to identify infected cells that 
inefficiently present protein antigens, thus providing a complementary mechanism.5 In 
addition, CD1 molecules are expressed on immature dendritic cells, suggesting that CD1-
restricted T-cells may function at an earlier phase of the immune response than MHC-
restricted T-cells.5 Finally, evasion of immune responses mediated by protein antigens may 
readily occur by point mutations that do not affect protein function, while (glyco)lipid 
structures are highly conserved (vide supra). However, by definition, the tailor-made 
system for an instant immune response against antigens with a common motif is the innate 
immune system. Hence, the first explanation for the existence of an adaptive immune 
system based on (glyco)lipids seems to be more plausible than the latter two arguments. 
4.3   CD1c-mediated T-cell recognition of isoprenoid glycolipids 
In 2000, it was reported that CD1c-presentation of two previously unknown -D-
mannosyl phospholipids (4.1 and 4.2) isolated from Mycobacterium tuberculosis resulted in 










example of a lipid antigen having a single alkyl chain instead of the more common motif of 
two straight aliphatic hydrocarbon tails connected by a central hydrophilic cap. To gain 
further insight into the molecular determinants that affect recognition, a range of semi-
synthetic glycosyl-1-phosphoisoprenoid compounds were prepared and tested. As 
predicted by the tri-molecular TCR-CD1-antigen model (§ 4.2.2 and Figure 4.3), the 
outcome demonstrated a fine specificity for the hydrophilic headgroup. Both removal of the 
mannose or exchange for glucose resulted in a complete loss of activity. In addition, a 
saturated -prenyl unit was required, but both cis and trans double bonds elsewhere in the 
alkyl chain were tolerated. Finally, T-cell response appeared inversely proportional to 
prenyl length. A glycolipid with an alkyl tail of 35 carbons responded stronger than one 
with a C55-tail, while the analogue with a C95-tail was completely inactive.   
Since the above study was performed using living cells rather than immobilized CD1 
proteins, it is unclear what is causing changes in TCR recognition. It could be that changes 
in the structure of the lipid antigen result in different affinity for the CD1 protein or that the 
CD1-antigen complex interacts differently with the TCR. However, it is also possible that 
modification of the lipid antigen influences intracellular trafficking and delivery of the 
glycolipids to relevant antigen-loading compartments. Likewise, it is also uncertain whether 
the fact that only CD1c presents lipid antigens with a single alkyl chain is due to 
specialization of the CD1c groove or to the loading pathway of the antigen. Related to this, 
the dilemma remains how the immune system discriminates between self  and foreign 
mannosyl-1-phosphate lipids.28 Even though a mannosyl-1-phosphate moiety with a 
saturated -prenyl unit and a short tail seems both necessary and sufficient for recognition, 
the saturated isoprenoid chain of -D-mannosyl phosphomycoketides has to be the key 
element responsible for selectivity. To obtain insight into the subtle mechanisms that  
underlie selectivity, complementary information should be acquired by in vitro and in vivo 
tests. A necessity for such experiments is the availability of sufficient and pure (glyco)lipid 
antigens of any desired composition. Considering the slow growth of M. tuberculosis and 
the minute amounts of -mannosyl phosphomycoketide that it produces, total synthesis 
seems to be the only way to fulfill this requirement at present. Assembly by total synthesis 
has the additional advantage that non-natural antigens are accessible as well. 
  
 







4.4   Biosynthesis of mycoketides26 
In the original paper on CD1c-mediated T-cell recognition of isoprenoid glycolipids the 
authors commented on the molecular structure of the antigens (4.1 and 4.2) in the following 
way: ‘Unusual features of the newly discovered mycobacterial isoprenoids (…) included 
the complete saturation of their alkyl chains, and a deviation from the repeating five carbon 
prenyl unit at the proximal and distal ends of these chains.’1 Since the structure of the 
saturated alkyl chain could not be explained by a conventional C5 isopentenyl 
pyrophosphate biosynthetic pathway, an investigation was started to determine the genetic 
and enzymatic basis of 4.1 and 4.2. Metabolic labeling and mass spectrometric analysis 
suggested an elongation mechanism using alternating C2 and C3 units, which is indicative 
for a polyketide synthase pathway. Inspection of the M. tuberculosis genome identified one 
candidate gene, pks12, which was predicted to encode a large protein consisting of 12 
contiguous but separately functioning catalytic domains. Knockout and complementation of 
pks12 established that this gene was indeed responsible for the production of the saturated 
isoprenoid tails of 4.1 and 4.2. As a consequence, 4.1 and 4.2 were thereafter referred to as 
mannosyl phosphomycoketides (MPM) rather than isoprenoids. Interestingly, mannosyl--
1-phospholipids with true polyisoprenol lipid moieties, with their biosynthesis not disrupted 
by pks12 genetic deletion, did not substitute as potent antigens for the T-cell response. 
During the elucidation of the biosynthetic pathway, MPM’s with a tail length of 31, 33 
and 34 carbons were observed next to the already known species with 30 (4.2) and 32 (4.1) 
carbons. A plausible polyketide based mechanism for the biosynthesis of all these 
structurally related mycoketides starts from different carboxylate primers of varying length. 
Subsequently, (two) acyltransferases and (two) ketosynthases add malonate (C2) and 
methylmalonate (C3) units in an alternating fashion. After every C2- or C3-addition, the 
consecutive action of a ketoreductase (to the alcohol), a dehydratase (to the alkene) and an 
enoylreductase provides the saturated system (see Scheme 2.1). Since C2-addition is 
followed by C3-addition and vice versa rather than at random, it is likely that two sets of 
catalytic domains are required, one for malonate units and one for methyl malonate units. 










following C3-addition. The final carboxylate moiety has to be reduced to the alcohol and 
phosphorylated to yield a substrate for glycosylation. 
The unraveling of the biosynthetic pathway of  MPM’s has raised speculations regarding 
their biological function. Their complex biosynthesis is energetically expensive and 
conserved in infectious mycobacteria while lacking in non-virulent mycobacteria. This 
suggests that they may have a highly specialized role that is essential for intracellular 
growth. In agreement with this hypothesis, MPM’s are found at low absolute levels; they 
make up about 1 ppm of the total weight of the cell wall. Possibly MPM’s are involved in 
mannose transmembrane transport or transfer.26 
4.5   Synthesis of stereorandom -D-mannosyl phosphomycoketides 
The central theme in the synthesis of  -D-mannosyl phosphomycoketides by Crich and 
Dudkin,2 was the formation of the -mannosyl phosphate linkage. As a result of steric 
repulsion caused by the 1,2-cis configuration and instability due to the anomeric effect, -
mannosyl glycosidic linkages in general are notoriously difficult to bring about.29 However, 
in a series of publications, Crich et al. disclosed an elegant method for the direct formation 
of such linkages.30 Their procedure involves in situ conversion of a 4,6-O-benzylidene 
protected -mannosyl sulfoxide (for example 4.3; Scheme 4.1) into the corresponding -
anomeric triflate. Subsequent addition of an acceptor leads to SN2 type displacement to give 
the desired -mannoside with high selectivity.31 The origin of this high selectivity lies in the 
torsional disarming propterties of the 4,6-O-benzylidene moiety, which opposes flattening 
of the molecule and thus prevents the formation of the oxocarbenium ion necessary for SN1 
type reactions.32 
In order to construct MPM 4.2, the general mannosylation protocol discussed above was 
applied to the coupling of sulfoxide donor 4.3, which was prepared in six steps from D-
mannose, to phosphate acceptor 4.4 (Scheme 4.1). Since formation of the -D-mannosyl 
phosphate linkage was the main goal of the investigation, a stereorandom mixture of 4.4 
was used consisting of 32 stereoisomers. In the event, 4.3 was reacted with Tf2O (1.1 eq) in 
toluene at -78 oC in the presence of acid scavenger 2,6-di-tert-butyl-4-methylpyridine 
(DTBMP), followed by the addition of three equivalences of 4.4 to give the desired product 
  
 







(4.5) in 49% yield after six hours. Subsequent deprotection via Birch reduction (Na, NH3) 



















   toluene, -78oC



















Scheme 4.1 Synthesis of racemic -D-mannosyl phosphomycoketide 4.2 by Crich et al.2 
4.6   Total synthesis of enantiopure -D-mannosyl phosphomycoketides 
To study the effect of the stereochemistry of the saturated alkyl chain on the activity of 
MPM’s, a synthetic protocol that is capable of accessing any desired diastereomer is 
required. Hence, we aimed at the development of a general (catalytic) strategy using 
enantiopure saturated isoprenoid building blocks (see chapter 3) as key intermediates.  
As explained in § 4.4, the stereochemistry of natural phosphomycoketides is determined 
by an enoylreductase following the introduction of methylmalonate. Provided that a single 
catalytic domain is responsible for this transformation, the product most likely has an all-
syn configuration.  Since the authors, who elucidated the biosynthetic pathway, predicted 
the stereochemistry to be all-S (private communication), we decided to direct our initial 
efforts to the preparation of this diastereomer of 4.1. 
4.6.1   Retrosynthesis 
When we started the synthesis of enantiopure MPM’s, we envisioned that three 










all, since connection of two saturated isoprenoid units (A and B in Figure 4.6) would 
generate an alkyl chain with four stereogenic centers, an additional (catalytic asymmetric) 
method had to be found for the introduction of the fifth asymmetric center (C). 
Conveniently, the catalytic asymmetric conjugate addition of Grignard reagents to ,-
unsaturated thioesters was under investigation in our group at that moment and we planned 
to employ this procedure to obtain fragment C.33 Secondly, as the various linear chiral 
building blocks (A, B and C) are relatively valuable, an efficient procedure had to be found 
to cross-couple them without using a large excess of either coupling partner. Related to this, 
formation of the -D-mannosyl phosphate linkage as described by Crich and Dudkin was 
undesirable,2,30g since it would require three equivalents of precious oligoisoprenoid chain. 
We therefore intended to either adapt their methodology in such a way that an excess of 
sulfoxide donor 4.3 could be used or to employ an entirely different coupling strategy. 


















Mannose + + 2
Na
C A and BD
 
Figure 4.6 Retrosynthetic analysis of -mannosyl phosphomycoketide 4.1. 
4.6.2   Synthesis of diisoprenoids 
The direct formation of sp3-sp3 carbon bonds in the presence of other functionalities, like 
for example (protected) alcohols or esters, is still a difficult transformation in organic 
synthesis. This particularly holds true when a large excess of either coupling partner has to 
be avoided, like in the synthesis of an expensive homo-chiral saturated isoprenoid chain. 
The classical method to cross-couple isoprenoids in order to obtain saturated diisoprenoids 
relies on an indirect approach. It consists of a SN2 reaction between an -deprotonated alkyl 
sulfone and an alkyl halide followed by a metal reduction (see scheme 3.1).34 However, the 
reductive removal of the sulfone proceeds under harsh conditions, that preclude the 
presence of, for example, esters. Moreover the yield in this second step is somewhat 
  
 







unreliable as it ranges from modest to good (50-85%). For the connection of our linear 
fragments, we decided to search for a milder and less capricious direct or indirect coupling 
procedure. 
4.6.2.1    Copper-catalyzed Grignard and SmI2-assisted cross-couplings 
In 1997, Berkowitz and Wu described the direct formation of saturated diisoprenoids via 
copper-catalyzed cross-couplings using Grignard and samarium chemistry.35 Our attempt to 
reproduce their results started with the protection of  the hydroxyl moiety of (3R,7S)-3.57 
via reaction with tert-butyldiphenylsilyl chloride (TBDPSCl) in the presence of imidazole 
(4.6, 95%, Scheme 4.2). The methyl ester was then reduced with DiBAl-H to afford 
primary alcohol 4.7 (97%). Subsequent treatment of 4.7 with either triphenylphosphine and 
NBS or with PPh3, iodine and imidazole furnished primary alkyl halides 4.8 (87%) and 4.9 
(93%), respectively. In an analogous fashion, (3R,7S)-3.57 was converted into primary 

















     imidazole, 30 min
2) DiBAl-H, THF,
     -78oC, 2 h
92%
4.7
4.8 X = Br
4.9 X = I
PPh3, I2, imidazole,
CH2Cl2, 2 h, 93% 4.9
PPh3, NBS, 
CH2Cl2, 1 h, 87% 4.8
PPh3, I2, imidazole,
CH2Cl2, 2 h, 83%
4.10
i)   SmI2 (3.0 eq), THF, HMPA,
ii)   4.9 (1.2 eq)
iii) CuBr
iv) 4.10, 30 min
i)  4.8 (1.1 eq), Mg (2.2 eq),
   THF, 40oC, 1 h
ii) Li2CuCl4, 4.10, THF,
    -78oC to rt, 2 d
X
 
Scheme 4.2 Preparation of diisoprenoids using Grignard/samarium cross-coupling. 
Disappointingly, Li2CuCl4-catalyzed Grignard coupling of 4.8 to 4.10 did not result in 










mediated cross-coupling of 4.9 and 4.10 in the presence of HMPA and catalytic copper 
bromide (20 mol%) was unsuccessful as well (lit.35 81%). 
Careful optimization of the SmI2-mediated reaction using comparable (non-chiral) 
compounds eventually gave yields of up to 40% in model reactions, while the isolated 
yields with magnesium were even lower. In the latter case, the problems were partly due to 
inefficient formation or instability (degradation and/or homocoupling) of the Grignard 
reagent. Titration with sec-butanol in the presence of 1,10-phenanthroline revealed that 
approximately only 60% of the alkyl bromide was converted into the corresponding active 
Grignard reagent. With regard to the SmI2-mediated reaction, the initial RSmI2 species (A, 
Figure 4.7) was readily formed as no starting alkyl halide was recovered. However, beside 
the desired cross-coupled product, side-products resulting from -elimination, -hydride 
transfer as well as homocoupling were observed by GC-MS.  
According to the proposed mechanism, acceleration of the desired reaction by increasing 
the catalyst loading is not possible unless the excess of starting alkyl halide (RI, Figure 4.7) 
is also increased.36 To start the catalytic cycle, part of species A has to form a complex (B) 
with CuBr  and this amount is thereafter permanently tied up in the catalytic cycle. As a 
consequence, an amount of the starting alkyl halide RI equal to the catalyst loading is lost 
by definition. All things considered, both coupling procedures were abandoned as they 
consistently gave poor yields and were unlikely to perform at an acceptable level in 














Figure 4.7 Proposed mechanism of the copper-catalyzed cross coupling of alkyl samarium 
reagents with alkyl halides.36  
4.6.2.2   Cross-couplings via formation of an olefin 
As an alternative approach, we focused our attention on coupling procedures which 
generate a carbon-carbon double bond, which would then later be reduced to the saturated 
  
 







system. In a comparative study, we evaluated the performance of the Wittig, the Horner-
Wadsworth-Emmons (HWE) and the Julia-Kocienski37 coupling for our system. The Julia-
Kocienski coupling is a one-pot procedure (Figure 4.8) derived from the Julia-Lythgoe 











































Figure 4.8 Mechanism of the Julia-Kocienski coupling.37 
The Wittig reagent 4.11 was obtained in 85% yield from alkyl bromide 4.8 via reaction 
with PPh3 (Scheme 4.3). Subjection of 4.8  to an Arbuzov reaction with triethylphosphite 
furnished HWE-reagent 4.12 (98%). Finally, the Julia-Kocienski sulfone was prepared 
from alcohol 4.7 via Mitsunobu reaction with 1-phenyl-1H-tetrazole-5-thiol (4.13, 91%) 
followed by oxidation of the resulting thioether with meta-chloroperbenzoic acid (mCPBA) 
to give 4.14 (95%).39 Compounds 4.11, 4.12 and 4.14 were subjected to coupling reactions 
with aldehyde 4.15, which was obtained in 97% yield from (3R,7S)-3.57 via oxidation with 
4-methylmorpholine N-oxide (NMO-oxide) in the presence of a catalytic amount of  tetra-
n-propylammonium perruthenate (TPAP).40 All three olefination reactions were performed 
in THF using a slight excess of 4.15 (1.1 eq) and potassium hexamethyldisilazane 
(KHMDS 1.0 eq) as the base. The Wittig reaction afforded diisoprenoid 4.16 in minute 
amounts (7%), while the desired product was not formed at all in the HWE-reaction. The 
Julia-Kocienski coupling gave the best result with an isolated yield of 57%. The reason 
why the Julia-Kocienski coupling performed better for this system than conventional 
Wittig- and HWE-reactions is unclear. 
The next goal was to convert the methyl-ester of 4.16 into a terminal linear saturated C7 
chain, for which we intended to employ the Grignard extension methodology already used 










was reduced to the corresponding primary alcohol 4.17 (98%) with DiBAl-H, after which 
reaction with p-toluenesulfonyl chloride in pyridine afforded 4.18 in 86% yield (Scheme 
4.4). Subsequent treatment with n-pentylmagnesium bromide and semi-catalytic 


















PPh3, CH3CN, 81oC, 12 h
85%
(EtO)3P, 140oC, 12 h
98%
4.8
1) PPh3, DIAD, Ph-tetrazole-thiol, 
    THF 0oC to rt, 1 h, 91%
2) mCPBA, CH2Cl2, 0oC to rt, 12 h, 95%














4.11: 7%, 4.12: no conv.
4.14: 57%
 
Scheme 4.3 Comparison of carbon-carbon double bond cross-coupling methods. 
4.16 TBDPSO
1) DiBAl-H, THF, -78oC, 2 h, 98%
CuBr·SMe2, n-C5H11MgBr,
THF, -78o to 0oC, 12 h






Scheme 4.4 Introduction of the saturated alkyl terminal chain. 
Although an isolated yield of 57% in the preparation of diisoprenoid 4.16 was 
acceptable, we decided to investigate whether removal of the ester in 4.15 would be 
beneficial for the Julia-Kocienski coupling. To this end, an isoprenoid building block was 
elongated to obtain the terminal n-heptyl function prior to cross-coupling (Scheme 4.5). 
This slightly modified approach had the additional advantage that it made the route 
somewhat more convergent.  
  
 









1) p-TsCl, pyridine, 0oC, 12 h, 86%
2) CuBr·SMe2, n-C5H11MgBr,
    THF, -78o to 0oC, 12 h, 97%
1) TBAF, THF, 2 h
2) TPAP, NMO-oxide,
    CH2Cl2, 30 min
72%
4.14, LiHMDS, THF,




1) TBAF, THF, 2 h
2) TPAP, NMO-oxide,





Scheme 4.5 Synthesis of diisoprenoid 4.25. 
The conversion of 4.7 into the corresponding tosylate 4.20 (86%) and the subsequent 
coupling with n-pentylMgBr to obtain 4.21 (97%) was performed as described for the 
transformation of  4.17 into 4.19. Treatment of 4.21 with TBAF yielded alcohol 4.22, after 
which oxidation with NMO-oxide and TPAP furnished aldehyde 4.23 (72% over 2 steps). 
Julia-Kocienski coupling of 4.23 to sulfone 4.14 under comparable conditions as for the 
preparation of 4.16, initially gave diisoprenoid 4.19 in similar yield (50-60%). However, 
changing the base from KHMDS to LiHMDS and mixing 4.23 and 4.14 prior to addition of 
the base (Barbier conditions) improved the yield to a gratifying 74%. It should be noted, 
that under these conditions, 4.19 was isolated as a mixture of cis/trans isomers 
(predominantly trans), whereas complete stereocontrol (only trans) was observed when 
KHMDS was used. Finally, the TBDPS-ether of 4.19 was cleaved and the resulting primary 
alcohol 4.24 was oxidized as before to give aldehyde 4.25 in 81% yield over two steps. 
4.6.3   Completion of the oligoisoprenoid chain 
As mentioned in paragraph 4.6.1, we intended to introduce the fifth methyl-branched 
stereogenic center (fragment C) using the asymmetric conjugate addition of Grignard 
reagents to ,-unsaturated thioesters.33  
Synthesis of a suitable substrate for the key reaction started from 1,4-butanediol, which 
was mono-protected via reaction with benzyl bromide and sodium hydride to give 4.26 in 
81% yield (Scheme 4.6). Even though the subsequent oxidation with pyridinium 










modest 61% yield due to the volatility of 4.27. Finally, Wittig reaction of 4.27 with 
PPh3CHCOSEt afforded ,-unsaturated thioester 4.28 as a mixture of cis/trans isomers.41 
Stirring of the mixture in the presence of 4-dimethylaminopyridine (DMAP) shifted the 
equilibrium towards the desired trans-isomer, which was isolated in 87% yield after 
separation from remaining traces of the cis-isomer by column chromatography. Conjugate 
addition of MeMgBr to 4.28 in the presence of catalytic CuBr·SMe2 (5 mol%) and chiral 
ferrocene-based ligand L*
 
(6 mol%) resulted in the formation of (3R)-4.29 (92%) with 
excellent stereoselectivity (93% ee).33 
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1) BnBr, DMF, THF, NaH,
    0oC to rt, 12 h, 81%







CHCl3, 60oC, 3 h,

























1) PPh3, DIAD, t-Bu-tetrazolethiol, 
    THF, 0oC to rt, 1 h, 85%




Scheme 4.6 Synthesis of linear chiral fragment C. 
In order to make fragment C suitable for cross-coupling, the thioester of 4.29 was 
reduced with LiAlH4 to provide the corresponding primary alcohol 4.30 in 96% yield. 
Subsequent Mitsunobu reaction of 4.30 with 1-tert-butyltetrazole-5-thiol (4.31, 85%) 
followed by oxidation with mCPBA provided sulfone (3R)-4.32 (95%). The rationale for 
the altered substitution moiety on the tetrazole ring in comparison to 4.14, is that tert-
butyltetrazolesulfones are known to often give superior yields, probably because of 
enhanced stability.42 In our case the improvement was not distinct, as LiHMDS-mediated 
Julia-Kocienski coupling of sulfone 4.32 to aldehyde 4.25 under Barbier conditions resulted 
in the formation of oligoisoprenoid 4.33 in 80% yield as a mixture of geometrical isomers 
(predominantly trans; Scheme 4.7). In comparison, coupling of 4.14 to 4.23 under identical 
  
 







conditions gave 4.19 in 74% yield (Scheme 4.5). The synthesis of the oligoisoprenoid chain 
was completed by simultaneous deprotection of the primary alcohol and hydrogenation of 
the double bonds via exposure to hydrogen over Pd/C to give 4.34 in 83% yield. With the 
privilege of hindsight, a diimide reduction or hydrogenation over a different catalyst like, 
for example, Wilkinson catalyst ((PPh3P)3RhCl) would have been a better choice to obtain 
the fully saturated system. Pd/C is known to occasionally cause migration of double bonds 
through reversible hydrometalation, which could lead to partial racemization of the 
stereogenic centers adjacent to the double bonds in our case.43 Extensive evaluation of 4.34 
by GC-analysis did not indicate that partial racemization/epimerization had indeed taken 
place. 
4.25 + 4.32 C7H15
4.33
LiHMDS, THF,
-78oC 3 h 
then rt 12 h
80%
BnO




Scheme 4.7 Completion of the oligoisoprenoid chain 4.34. 
4.6.4   Formation of the -D-mannosyl phosphate linkage 
4.6.4.1   Modification of Crich’s -mannosylation protocol 
Our first attempt to install the -D-mannosyl phosphate linkage, was based on 
modification of Crich’s -mannosylation protocol (Scheme 4.1). We wondered how their 
approach would perform when a surplus of sulfoxide donor 4.3 was used rather than an 
excess of phosphate acceptor. To synthesize the appropriate phosphate acceptor, 
phosphoramidite 4.35 was prepared in 64% yield by reaction of benzyl alcohol with 
commercial 2-cyanoethyl N,N-diisopropylchlorophosphoramidite in the presence of 
Hunig’s base (Scheme 4.8).2 Subsequent tetrazole-mediated substitution of the 
diisopropylamine moiety of 4.35 by enantiopure saturated oligoisoprenoid 4.34 followed by 
oxidation of the resulting phosphite with tert-butyl hydroperoxide yielded phosphate ester 
4.36 in 92%. Finally, treatment of 4.36 with tetra-n-butylammonium hydroxide in a 














i) 4.34, CH3CN, 
    1H-tetrazole, 1.5 h





























Scheme 4.8 Synthesis of tetra-n-butylammonium phosphate acceptor 4.37. 
To find the optimal coupling conditions, sulfoxide 4.3 was first connected to 4.38, a 
racemic analogue of 4.37 which was synthesized from phytol (Scheme 4.9). Reproduction 
of Crich’s procedure using three equivalents of 4.38 resulted in the isolation of 4.39 in 37% 
yield (literature30g: 56%). The mass balance was made up mainly by the hydrolysis product 
of 4.3, indicating that formation of the triflate was quantitative. When the amount of 4.38 
was lowered to 1.5 equivalences, the yield of 4.39 dropped to 16%. Disappointingly, all 
reactions in which an excess of 4.3 was used failed to provide the desired product at all. 
The only attempt to couple 4.3 to enantiopure acceptor 4.37 (2.2 eq.) furnished the coupled 











   toluene, -78oC





























   toluene, -78oC
ii) 4.37 (2.2 eq), 6 h
10%
 
Scheme 4.10 Formation of the -mannosyl phosphate linkage using Crich’s protocol. 
  
 







4.6.4.2   Reversed strategy; synthesis of a -mannosyl phosphate ester and coupling to 4.34 
As an alternative approach, we decided to first install a -phosphate moiety on a suitably 
protected mannopyranose, and then to connect the resulting -mannosyl phosphate ester to 
the enantiopure oligoisoprenoid alcohol 4.34 (Scheme 4.11). To this end, diphenyl 
chlorophosphate was slowly added to a solution of 2,3,4,6-tetra-O-acetyl-D-mannose in the 
presence of excess DMAP at room temperature to give predominantly the -anomer of 
mannosyl phosphate triester 4.41 (79%, : = 1:4).44 The anomers were separated by 
column chromatography and the -anomer proved to be stable in solution (CDCl3) at room 
temperature. Remarkably, epimerization to the -anomer did take place when 4.41 was 
concentrated, but this could be prevented by storage at -18 oC. Removal of the phenyl 
groups of -4.41 was achieved by hydrogenation over Adam’s catalyst (PtO2)44 to give 
pyridinium salt -4.42 (80%) after quenching with pyridine. Subsequent coupling of an 
excess of readily available -4.42 (2.0 eq) to enantiopure 4.34 (1.0 eq) in the presence of  
2,4,6-triisopropylbenzenesulfonyl chloride (TPSCl; 3.0 eq) proceeded  readily to give 4.43 
in a gratifying 79% yield after four days.45 The employment of a sterically hindered 
arenesulfonyl chloride served to prevent sulfonylation of the primary alcohol of 4.34 which 
could otherwise compete with the desired phosphorylation reaction.46 Finally, deacetylation 
with NaOMe in a mixture of chloroform and methanol afforded the target molecule (all-S)-














i)  CH2Cl2, DMAP, rt,
ii) (PhO)2P(O)Cl over 1 h,
    then stirring for 2 h
i)  PtO2, H2, 

















































Scheme 4.11 Completion of the synthesis; selective formation of  a -mannosyl phosphate 










4.6.5   Synthesis of analogues 
For analytical and biological comparison, the -anomer of (all-S)-4.1 was synthesized as 
well. In the event, -4.41 was selectively prepared in 65% isolated yield by simultaneous 
addition of diphenyl chlorophosphate and DMAP to a solution of 2,3,4,6-tetra-O-acetyl-D-
mannose at -30 oC (Scheme 4.12).44 The origin of this remarkable change in the 
stereochemical outcome of the phosphorylation reaction by a slight modification of the 
reaction conditions is related to the equilibrium between the two anomers of the starting 
material and their difference in reactivity. Due to the anomeric effect as well as the axial 
substituent at the neighboring carbon, the starting mannosylpyranose exists for over 85% as 
the -anomer.44 However, the same effects that cause instability of the -anomer are also 
grounds for increased reactivity.47 Hence, reaction in the presence of excess base (DMAP), 
which catalyzes the anomerization of the - to the less stable -form, mainly gives the 
kinetic -product at room temperature. In contrast, simultaneous addition of the base and 
the phosphorylating agent results in the formation of exclusively the thermodynamic -
product at -30 oC. Conversion of  -4.41 into (all-S)--4.1 was performed in 49% overall 
yield following the same route as for the preparation of (all-S)--4.1. 
i)   CH2Cl2, -30oC,
ii)  (PhO)2P(O)Cl, DMAP



















Scheme 4.12 Synthesis of the -mannosyl phophomycoketide analogue. 
To determine whether the (all-S)-phosphomycoketide, without the mannose headgroup, 
would show any biological activity, this compound was synthesized in two steps from 
enantiopure alcohol 4.34. DMAP-assisted phosphorylation of 4.34 provided diphenyl 
phosphate triester 4.44, after which hydrogenation over Adam’s catalyst followed by 








1)  CH2Cl2, DMAP,
     (OPh)2P(O)Cl
     0oC to rt, 12 h
HNEt3
2) PtO2, H2, EtOAc,
    EtOH, then Et3N
 
Scheme 4.13 Synthesis of a phosphomycoketide analogue. 
  
 







4.6.6   Proof of the anomeric configuration 
Proof of the anomeric configuration of (all-S)--4.1 commenced with a mass 
spectrometric investigation employing the same technique as was used in the structural 
elucidation of the natural product. Indeed, low-energy collisionally induced dissociation 
tandem mass spectrometry (ESI-CID-MS/MS) of (all-S)--4.1 nicely reproduced the 
spectrum of the natural product (Figure 4.9).1 Thus, a cross-ring fragmentation (m/z 587.7) 
of the carbohydrate moiety and a dehydration fragment (m/z 689.5) which are both 
characteristic for cis-1,2-glycosyl phosphates were observed.48 In contrast, (all-S)--4.1 
produced a clearly different spectrum with the main fragment (m/z 545.5) originating from 
cleavage of the phosphomycoketide chain at the anomeric center. 
 
 
Figure 4.9 Low energy CID-MS/MS spectra of -and -(all-S)-4.1 and natural 4.1.1 
The anomeric configuration of (all-S)--4.1 was confirmed by the NOE correlation 
between the anomeric hydrogen and H3 and H5 of the mannose moiety (1,3-diaxial 
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constants, which as predicted by literature,49 amounted to 169 Hz for the -anomer and 159 
Hz for the -anomer. A final clue came from the 1H-NMR spectra, which showed a clear 
difference in the chemical shift of the alpha- ( = 5.38 ppm) and the beta ( = 5.05 ppm) 
anomeric hydrogen (Figure 4.10; anomeric hydrogens depicted in inset). 
 
Figure 4.10 Comparison of part of the 1H-NMR spectra of the two anomers of (all-S)-4.1; 
insert: anomeric protons. 
4.7   Biological activity 
 In order to evaluate the biological activity of (all-S)--4.1, (all-S)--4.1 and (all-S)-
4.45, the compounds were tested in a dose-dependent manner in T-cell proliferation assays 
by Dr. Moody and co-workers.50 CD8-1 T-cells (CD8+TCR) were cultured with CD1c+ 
antigen presenting cells in the presence or absence of synthetic antigen. As an index of 
antigen-specific activation, interleukin-2 production was measured, which is secreted by 
CD8-1 T-cells to stimulate (among others) the proliferation of type 2 helper T-cells (HT-2 
cells). In practice, an aliquot of the supernatant was removed from the bio-assay and 
diluted, after which HT-2 cells were cultured in this medium in the presence of 
[3H]thymidine. The amount of [3H]thymidine incorporated in DNA was measured with a 
liquid scintillation counter to give the Interleukin-2 production in counts per minute (CPM).  
 In agreement with the tri-molecular CD1-lipid-TCR model (§ 4.2.2), 
phosphomycoketide 4.45, without the mannose moiety, did not show any activity unless 
elevated concentrations were used (> 10 M) in which case activity might be caused by in 
situ mannosylation (Figure 4.11). In addition, comparison of  (all-S)--4.1 and (all-S)--4.1 
showed, that a relatively small structural change in the polar epitope already results in a 

















Figure 4.11 Biological activity of different synthetic MPM’s. 
 





























































has a considerably higher activity than stereorandom--4.2. It appears that, contrary to what 
was assumed so far, (the stereochemistry of) the oligoisoprenoid side-chain does have a 
pronounced effect on the activity. Finally, assessment of (all-S)--4.1 in comparison to the 
natural product demonstrated that both compounds have identical activity within the margin 
of error (Figure 4.12). Obviously, this is an indication that the stereochemistry of the 
natural product could very well be all-S, although it is certainly no definite proof. 
4.8   Summary and concluding remarks 
 In this chapter the first total synthesis of an enantiopure -mannosyl 
phosphomycoketide (MPM) was described. To this end, a general and fully catalytic 
method for the preparation of enantiopure, saturated oligoisoprenoids of any desired length 
and stereochemistry was developed. In the event, two different conjugate addition reactions 
were employed to introduce the stereogenic centers with complete control over the absolute 
configuration, after which a Julia-Kocienski sequence was used to cross-couple the various 
linear enantiopure fragments. Using this strategy, penta-methyl-branched aliphatic alcohol 
4.34 was prepared, with all stereogenic centers having the S-configuration. Low yields at 
the final stage of the synthesis due to the difficult nature of the -mannosyl phosphate 
linkage were circumvented by installation of the phosphate moiety on a suitably protected 
mannopyranose prior to coupling to enantiopure 4.34. Using this convergent approach, the 
total synthesis of (all-S)--4.1 was achieved in 6.7% overall yield and a longest linear 
sequence of eighteen steps. In addition, the analogues (all-S)--4.1 as well as (all-S)-4.45, 
which lacks the mannose unit, were prepared following similar routes. 
Biological evaluation revealed that (all-S)--4.1 and the natural product have identical 
activity, whereas an analogue with an oligoisoprenoid chain consisting of a mixture of 32 
stereoisomers is significantly less active. The latter result implicates that the fine structure 
of the saturated alkyl chain influences biological activity to a far greater extent than 
assumed until now. From a biological point of view, in vitro and in vivo testing of a library 
of MPM’s with variations in both the length and the stereochemistry of the oligoisoprenoid 
chain would be very helpful in acquiring detailed knowledge regarding the relationship 
between structure and activity. Since the synthesis of such a library is a laborious process, 
an X-ray structure of a CD1c-protein complexed to a -mannosyl phosphomycoketide 
  
 







antigen would be useful to set certain initial boundaries. At present, attempts are being 
made to co-crystallize a CD1c-protein and a molecule of synthetic (all-S)--4.1. If 
succesful, the next objective would be to include a T-cell-receptor as well, which would 
provide the first direct structural evidence for the existence of the trimolecular complex 
(Figure 4.3).  
4.9   Experimental section 
For general information: see Chapter 2 and 3. HPLC analysis to determine the 
enantiomeric excess of 4.29 was carried out on a Shimadzu LC-10ADVP HPLC equipped 
with a Shimadzu SPD-M10AVP diode array detector. Racemic 4.29 was prepared by 
reaction of 4.28 with MeMgBr at -78oC in THF in the presence of CuI and TMSCl. 
 
Phenyl-2,3-Di-O-benzyl-4,6-O-benzylidene-1-deoxy-1-thio--D-mannospyranoside S-
oxide (4.3):30f,51c  Sulfoxide donor 4.3 was prepared in six steps 
from mannose using literature procedures. 30f,51 NMR-data were 
as reported in the literature.30f,51c 1H-NMR (CDCl3, 400 MHz)  
= 3.77 (t, J = 10.0 Hz, 1H), 4.12 (m, 1H), 4.23 (dd, J = 4.8, 10.4 
Hz, 1H), 4.28-4.41 (m, 3H), 4.52 (brs, 1H), 4.57 (d, J = 11.6 
Hz, 1H), 4.61 (d, J = 12.0 Hz, 1H), 4.68 (d, J = 12.0 Hz, 1H), 4.84 (d, J = 12.0 Hz, 1H), 
5.65 (s, 1H), 7.21-7.43 (m, 15H), 7.49-7.58 (m, 5H) ppm. MS(CI) for C33H32O6S: m/z = 
574 (M + NH4)+. 
 
 
8-(tert-Butyl-diphenyl-silanyloxy)-(3R,7S)-3,7-dimethyl-octanoic acid methyl ester 
(4.6):35 (3R,7S)-3.57 (1.62 g, 8.01 mmol) was dissolved 
in DMF (12.4 mL) and imidazole (1.09 g, 16.0 mmol, 
2.0 eq) and TBDPSCl (4.15 mL, 16.0 mmol, 2.0 eq) 
were added. The resulting solution was stirred for 30 min under argon at room temperature, 
after which TLC showed complete conversion. The solution was diluted with water, 
extracted with Et2O (3x) and the combined organic layers were washed with brine (sat.), 
dried (Na2SO4) and concentrated. 4.6 (3.34 g, 7.58 mmol, 95%) was isolated as a colorless 
oil after column chromatography (n-pentane-Et2O 9:1). (3R,7S)-4.6: []D22 = +1.7o (c = 
1.97, CHCl3), 1H-NMR (CDCl3, 400 MHz)  = 0.91 (d, J = 6.4 Hz, 6H), 1.05 (s, 9H), 1.06-
1.45 (m, 6H), 1.63 (m, 1H), 1.93 (m, 1H), 2.09 (dd, J = 8.4, 14.8 Hz, 1H), 2.29 (dd, J = 6.0, 
14.8 Hz, 1H), 3.43 (dd, J = 6.4, 9.6 Hz, 1H), 3.50 (dd, J = 5.6, 9.6 Hz, 1H), 3.66 (s, 3H), 
7.35-7.44 (m, 6H), 7.65-7.68 (m, 4H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 16.8 (q), 
19.1 (s), 19.6 (q), 24.1 (t), 26.8 (q), 30.2 (d), 33.1 (t), 35.5 (d), 36.9 (t), 41.5 (t), 51.2 (q), 
68.7 (t), 127.4 (d), 129.4 (d), 134.0 (s), 135.5 (d), 173.5 (s) ppm. MS(CI) for C27H40O3Si: 




















8-(tert-Butyl-diphenyl-silanyloxy)-(3R,7S)-3,7-dimethyl-octan-1-ol (4.7):35 To a solution 
of  4.6 (870 mg, 1.97 mmol) in THF (8.5 mL) at -78 oC was added a solution of Dibal-H 
(20 wt% in toluene, 8.3 mL, 10.1 mmol, 5.0 eq) and the 
resulting mixture was stirred for 2 h at -78 oC under 
argon, after which TLC showed complete conversion. 
The reaction was quenched with aq. NH4Cl (sat.) and then diluted with Et2O and aq. HCl 
(1.0 M) until a clear solution was obtained. The aqueous layer was extracted with Et2O (3x) 
and the combined organic layers were washed with aq. NaHCO3 (sat.) and brine (sat.), 
dried (Na2SO4) and concentrated. The product 4.7, 792 mg, 1.92 mmol, 97%) was isolated 
as a colorless oil after column chromatography (n-pentane-EtOAc 4:1). (3R,7S)-4.7: []D22 
= +0.5o (c = 2.00, CHCl3), 1H-NMR (CDCl3, 400 MHz)  = 0.88 (d, J = 6.8 Hz, 3H), 0.92 
(d, J = 6.4 Hz, 3H), 1.05 (s, 9H), 1.06-1.70 (m, 10H), 3.43 (dd, J = 6.4, 9.6 Hz, 1H), 3.51 
(dd, J = 5.6, 9.6 Hz, 1H), 3.67 (m, 2H), 7.35-7.44 (m, 6H), 7.65-7.68 (m, 4H) ppm. 13C-
NMR (CDCl3, 100.6 MHz)  = 16.8 (q), 19.2 (s), 19.5 (q), 24.1 (t), 26.7 (q), 29.3 (d), 33.2 
(t), 35.5 (d), 37.3 (t), 39.7 (t), 61.0 (t), 68.7 (t), 127.4 (d), 129.3 (d), 133.9 (s), 135.5 (d) 
ppm. MS(CI) for C26H40O2Si: m/z = 430 (M + NH4)+, HRMS calcd for C26H40O2Si-C4H9: 
355.209, found: 355.207. 
 
 (8-Bromo-(2S,6R)-2,6-dimethyl-octyloxy)-tert-butyl-diphenyl-silane (4.8):35 To a 
solution of 4.7 (188 mg, (0.46 mmol) in dichloromethane 
(1.6 mL) were added PPh3 (143 mg, 0.55 mmol, 1.2 eq) 
and then NBS (97 mg, 0.55 mmol, 1.2 eq) at 0 oC. The 
resulting solution was stirred under argon at 0 oC for 10 min and then warmed to room 
temperature over 1 h. The reaction mixture was quenched with aq. NaHCO3 (sat.) and the 
aqueous layer was extracted with dichloromethane (3x). The combined organic layers were 
washed with aq. Na2S2O3 (10% w/w) and brine (sat.), dried (Na2SO4), filtered and 
concentrated. The resulting brown solid was suspended in n-pentane and filtered, after 
which the residue was washed with n-pentane. The filtrate was concentrated and further 
purified by column chromatography (n-pentane-Et2O 99:1) to give 4.8 (191 mg, 0.40 mmol, 
87%) as a colorless oil. (2S,6R)-4.8: []D22 = -4.1o (c = 1.36, CHCl3),1H-NMR (CDCl3, 400 
MHz)  = 0.93 (d, J = 6.4 Hz, 3H), 1.00 (d, J = 6.8 Hz, 3H), 1.14 (s, 9H), 1.10-1.54 (m, 
7H), 1.70 (m, 2H), 1.92 (m, 1H), 3.41-3.53 (m, 2H), 3.52 (dd, J = 6.4, 10.0 Hz, 1H), 3.59 
(dd, J = 5.6, 9.6 Hz, 1H), 7.40-7.50 (m, 6H), 7.72-7.77 (m, 4H) ppm. 13C-NMR (CDCl3, 
100.6 MHz)  = 16.9 (q), 18.8 (q), 19.2 (s), 24.0 (t), 26.8 (q), 31.5 (d), 32.0 (t), 33.2 (t), 
35.5 (d), 36.6 (t), 39.9 (t), 68.7 (t), 127.4 (d), 129.4 (d), 133.9 (s), 135.5 (d) ppm. MS(CI) 
for C26H39BrOSi: m/z = 494 (M + NH4)+. HRMS calcd for C26H39BrOSi-C4H9: 417.125, 
found: 417.126. 
 
tert-Butyl-(8-iodo-(2S,6R)-2,6-dimethyl-octyloxy)-diphenyl-silane (4.9):35 To a solution 
of PPh3 (272 mg, 1.04 mmol, 1.2 eq) in dichloromethane 
(2.5 mL) were added imidazole (70 mg, 1.04 mmol, 1.2 eq) 
and iodine (262 mg, 1.04 mmol, 1.2 eq) and the resulting 
mixture was stirred under argon for 5 min. Subsequently, a solution of 4.7 (356 mg, 0.86 
mmol) in dichloromethane (1.2 mL) was added and the mixture was stirred for 2 h, after 
which the reaction was quenched with aq. NaHCO3 (sat.). The aqueous layer was extracted 
















(10% w/w) and brine (sat.), dried (Na2SO4), filtered and concentrated. The resulting white 
solid was suspended in n-pentane and filtered, after which the residue was washed with n-
pentane. The filtrate was concentrated and further purified by column chromatography (n-
pentane-Et2O 99:1 to 98:2) to give 4.9 (418 mg, 0.80 mmol, 93%) as a colorless oil. 1H-
NMR (CDCl3, 400 MHz)  = 0.86 (d, J = 6.4 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H), 1.06 (s, 
9H), 1.06-1.67 (m, 9H), 1.86 (m, 1H), 3.17 (m, 1H), 3.24 (m, 1H), 3.44 (dd, J = 6.0, 10.0 
Hz, 1H), 3.51 (dd, J = 5.6, 10.0 Hz, 1H), 7.36-7.45 (m, 6H), 7.65-7.68 (m, 4H) ppm. 13C-
NMR (CDCl3, 100.6 MHz)  = 5.2 (t), 16.9 (q), 18.6 (q), 19.2 (s), 24.0 (t), 26.8 (q), 33.2 (t), 
33.7 (d), 35.6 (d), 36.4 (t), 40.8 (t), 68.7 (t), 127.4 (d), 129.4 (d), 134.0 (s), 135.5 (d) ppm. 
MS(CI) for C26H39IOSi: m/z = 540 (M + NH4)+. 
 
8-Iodo-(3R,7S)-3,7-dimethyl-octanoic acid methyl ester (4.10):35 To a solution of PPh3 
(207 mg, 0.79 mmol, 1.2 eq) in dichloromethane (1.9 mL) 
were added imidazole (54 mg, 0.79 mmol, 1.2 eq) and iodine 
(200 mg, 0.79 mmol, 1.2 eq) and the resulting mixture was 
stirred under argon for 5 min. Subsequently, a solution of (3R,7S)-3.57 (133 mg, 0.66 
mmol) in dichloromethane (0.94 mL) was added and the mixture was stirred for 2 h, after 
which the reaction was quenched with aq. NaHCO3 (sat.). The aqueous layer was extracted 
with dichloromethane (3x) and the combined organic layers were washed with aq. Na2S2O3 
(10% w/w) and brine (sat.), dried (Na2SO4), filtered and concentrated. Purification by 
column chromatography (n-pentane-Et2O 85:15) provided 4.10 (171 mg, 0.55 mmol, 83%) 
as a colorless liquid. 1H-NMR (CDCl3, 400 MHz)  = 0.90 (d, J = 6.4 Hz, 3H), 0.94 (d, J = 
6.4 Hz, 3H), 1.11-1.45 (m, 7H), 1.92 (m, 1H), 2.09 (dd, J = 8.0, 14.8 Hz, 1H), 2.26 (dd, J = 
6.0, 14.8 Hz, 1H), 3.12 (dd, J = 5.6, 9.6 Hz, 1H), 3.19 (dd, J = 4.8, 9.6 Hz, 1H), 3.63 (s, 
3H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 17.6 (t), 19.5 (q), 20.4 (q), 24.0 (t), 30.0 (d), 
34.4 (d), 36.3 (t), 36.4 (t), 41.4 (t), 51.2 (q), 173.4 (s) ppm. MS(CI) for C11H21IO2: m/z = 
330 (M + NH4)+. 
 
 [8-(tert-Butyl-diphenyl-silanyloxy)-(3R,7S)-3,7-dimethyl-octyl]-triphenyl-
phosphonium; bromide (4.11): To a solution of 4.8 
(197 mg, 0.41 mmol) in acetonitrile (4.0 mL) was 
added PPh3 (130 mg, 0.50 mmol, 1.2 eq) and the 
resulting mixture was heated under reflux overnight. After cooling to room temperature, the 
reaction mixture was concentrated in vacuo. Purification by column chromatography (first 
n-pentane-Et2O 98:2 to regain 4.8 and then dichloromethane-MeOH 95:5) furnished 4.11 
(259 mg, 0.35 mmol, 85%) as a white solid. (3R,7S)-4.11: []D22 = -4.4o (c = 1.13, CHCl3), 
1H-NMR (CDCl3, 400 MHz)  = 0.82 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H), 0.99 (s, 
9H), 1.00-1.42 (m, 7H), 1.55 (m, 2H), 1.68 (m, 1H), 3.34 (dd, J = 6.4, 10.0 Hz, 1H), 3.43 
(dd, J = 6.0, 10.0 Hz, 1H), 3.59 (m, 2H), 7.28-7.36 (m, 6H), 7.58-7.68 (m, 10H), 7.72-7.81 
(m, 9H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 16.6 (q), 18.9 (q), 19.0 (s), 20.4 + 20.9 (t, 
JC-P = 50.7 Hz), 23.8 (t), 26.6 (q), 29.0 (t, JC-P = 4.6 Hz), 33.0 (t), 33.3 (d), 35.4 (d), 36.5 (t), 
68.6 (t), 117.5 + 118.4 (s, JC-P = 85.9 Hz), 127.3 (d), 129.2 (d), 130.2 (d, J = 13.1 Hz), 

















diethyl ester (4.12): A solution of 4.8 (197 mg, 
0.41 mmol) in triethylphosphite (1.0 mL) was 
heated overnight at 140 oC while protected from 
moisture by a CaCl2-tube. The reaction mixture was cooled to room temperature and then 
concentrated in vacuo. Purification by column chromatography (n-pentane-EtOAc 4:1 to 
1:1) gave 4.12 (215 mg, 0.40 mmol, 98%) as a colorless oil. (3R,7S)-4.12: []D22 = +1.7o (c 
= 1.39, CHCl3), 1H-NMR (CDCl3, 400 MHz)  = 0.84 (d, J = 6.4 Hz, 3H), 0.90 (d, J = 7.2 
Hz, 3H), 1.04 (s, 9H), 1.04-1.44 (m, 7H), 1.30 (t, J = 7.2 Hz, 6H), 1.53-1.80 (m, 3H), 3.42 
(dd, J = 6.4, 10.0 Hz, 1H), 3.49 (dd, J = 6.0, 10.0 Hz, 1H), 4.00-4.15 (m, 6H), 7.30-7.42 (m, 
6H), 7.63-7.67 (m, 4H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 16.3 (q, JC-P = 6.1 Hz), 
16.7 (q), 18.9 (q), 19.1 (s), 22.4 + 23.8 (t, JC-P = 140 Hz), 24.1 (t), 26.7 (q), 28.9 (t, J = 5.3 
Hz), 33.2 (t), 33.3 (d), 35.5 (d), 36.4 (t), 61.2 (t, JC-P = 6.1 Hz), 68.7 (t), 127.4 (d), 129.3 
(d), 133.9 (s), 135.4 (d) ppm. MS(EI) for C30H49O4PSi-CH3: m/z = 517 [M - CH3]+. HRMS 
calcd for C30H49O4PSi-CH3: 517.290, found: 517.291. 
 
5-[8-(tert-Butyl-diphenyl-silanyloxy)-(3R,7S)-3,7-dimethyl-octylthio]-1-phenyl-1H-
tetrazole (4.13): To a solution of 4.7 (450 mg, 
1.09 mmol) and 1-phenyl-1H-tetrazole-5-thiol (389 
mg, 2.18 mmol, 2.0 eq) in THF (10.0 mL) was 
added PPh3 (430 mg, 1.64 mmol, 1.5 eq) at 0 oC. 
Subsequently, DIAD (0.38 mL, 1.9 mmol, 1.8 eq) was added dropwise over 2 min and the 
resulting solution was stirred under argon while warming to room temperature. After 1 h 
TLC showed complete conversion and the reaction was quenched with brine (sat.). The 
aqueous layer was extracted with Et2O (3x) and the combined organic layers were dried 
(MgSO4) and concentrated. Purification by column chromatography (n-pentane-EtOAc 9:1) 
gave 4.13 (571 mg, 1.00 mmol, 91%) as a colorless oil. (3R,7S)-4.13: []D22 = -4.3o (c = 
1.96, CHCl3), 1H-NMR (CDCl3, 400 MHz)  = 0.92 (dd, J = 5.6, 6.4 Hz, 6H), 1.06 (s, 9H), 
1.06-1.70 (m, 9H), 1.81 (m, 1H), 3.34-3.54 (m, 4H), 7.36-7.44 (m, 6H), 7.51-7.60 (m, 5H), 
7.67-7.69 (m, 4H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 16.8 (q), 19.0 (q), 19.2 (s), 24.0 
(t), 26.7 (q), 31.2 (t), 32.0 (d), 33.2 (t), 35.5 (d), 35.8 (t), 36.7 (t), 68.7 (t), 123.7 (d), 127.4 
(d), 129.3 (d), 129.6 (d), 129.9 (d), 133.6 (s), 133.9 (s), 135.5 (d) 154.3 (s) ppm. MS(CI) for 
C33H44N4OSSi: m/z = 573 (M + H)+, 590 (M + NH4)+, HRMS calcd for C33H44N4OSSi-
C4H9: 515.230, found: 515.230. 
 
5-[8-(tert-Butyl-diphenyl-silanyloxy)-(3R,7S)-3,7-dimethyl-octane-1-sulfonyl]-1-
phenyl-1H-tetrazole (4.14): 4.13 (570 mg, 0.99 
mmol) was dissolved in dichloromethane (5.5 mL) 
and mCPBA (70%, 1.23 g, 4.97 mmol, 5.0 eq) was 
added at 0 oC. The resulting suspension was 
warmed to room temperature and stirred overnight. The reaction was quenched with aq. 
Na2S2O3 (10% w/w) and diluted with dichloromethane. The organic layer was washed with 
aq. Na2S2O3 (10% w/w, 3x; no more peroxides present) and the combined aqueous layers 
were subsequently extracted with dichloromethane (3x). The combined organic layers were 
washed with aq. NaHCO3 (sat. 3x) and brine (sat.), dried (MgSO4) and concentrated. The 
























mg, 0.95 mmol, 95%) as a colorless oil. (3R,7S)-4.14: []D22 = -4.1o (c = 1.74, CHCl3), 1H-
NMR (CDCl3, 400 MHz)  = 0.94 (t, J = 7.2 Hz, 6H), 1.07 (s, 9H), 1.07-1.48 (m, 6H), 1.64 
(m, 2H), 1.77 (m, 1H), 1.96 (m, 1H), 3.49 (m, 2H), 3.74 (m, 2H), 7.37-7.45 (m, 6H), 7.57-
7.64 (m, 3H), 7.67-7.72 (m, 6H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 16.7 (q), 18.9 
(q), 19.2 (s), 23.9 (t), 26.7 (q), 28.2 (t), 31.8 (d), 33.1 (t), 35.5 (d), 36.4 (t), 54.1 (t), 68.6 (t), 
124.9 (d), 127.4 (d), 129.4 (d), 129.5 (d), 131.3 (d), 132.9 (s), 133.9 (s), 135.5 (d) 153.3 (s) 
ppm. MS(CI) for C33H44N4O3SSi: m/z = 622 (M + NH4)+, HRMS calcd for C33H44N4O3SSi-
C4H9: 547.220, found: 547.223. 
 
 (3R,7S)-3,7-Dimethyl-8-oxo-octanoic acid methyl ester (4.15): (3R,7S)-3.57 (50 mg, 
0.25 mmol) was dissolved in dichloromethane (2.3 mL) and 
NMO-oxide (43 mg, 0.37 mmol, 1.5 eq) and TPAP (17 mg, 
49 mol, 0.20 eq) were added. The resulting black solution 
was stirred for 30 min under argon, after which TLC showed conversion into a single 
product. The reaction mixture was brought directly onto a silica column and flushed with a 
mixture of n-pentane-EtOAc (95:5 to 9:1) to give pure 4.15 (48 mg, 0.24 mmol, 97%) as a 
colorless liquid after concentration. Because the product was particularly sensitive to 
oxidation, the pressure after concentration in vacuo was equalized with nitrogen instead of 
air and 6 was immediately used in the next step. 1H-NMR (CDCl3, 400 MHz)  = 0.91 (d, J 
= 6.4 Hz, 3H), 1.08 (d, J = 6.8 Hz, 3H), 1.12-1.40 (m, 5H), 1.69 (m, 1H), 1.94 (m, 1H), 
2.11 (dd, J = 8.0, 14.8 Hz, 1H), 2.28 (dd, J = 6.0, 14.8 Hz, 1H), 2.32 (m, 1H), 3.65 (s, 3H), 
9.59 (d, J = 2.0 Hz, 1H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 13.2 (q), 19.5 (q), 24.1 







enoic acid methyl ester (4.16): The experiment using sulfon 4.14 is described; procedures 
with Wittig reagent 4.11 and HWE-reagent 4.12 were performed in an analogous fashion. 
KHMDS (0.5 M in toluene, 0.69 mL, 0.35 mmol, 1.0 eq) was added in a dropwise fashion 
to a solution of 4.14 (196 mg, 0.32 mmol, 1.0 eq) in THF (4.0 mL) at -78 oC resulting in a 
bright yellow solution. This mixture was stirred for 30 min under argon, after which 4.15 
(73 mg, 0.36 mmol, 1.1 eq) in THF (4.0 mL) was added over 10 min. The solution was 
stirred for 3 h at -78 oC and then stirred overnight while slowly warming to room 
temperature. The reaction was quenched with water and the aqueous layer was extracted 
with Et2O (3x). The combined organic layers were washed with brine (sat.), dried (MgSO4) 
and concentrated. Purification by column chromatography (n-pentane:Et2O 98:2) gave 4.16 
(106 mg, 0.18 mmol, 57%) as a colorless oil. In addition to 4.16, several side products were 
observed, but due to the complexity of the mixture their structure could not be elucidated. 
(3R,7S,11R,15S)-4.16: []D22 = +9.4o (c = 1.70, CHCl3),  1H-NMR (CDCl3, 400 MHz)  = 
0.83 (d, J = 6.8 Hz, 3H), 0.92 (m, 6H), 0.95 (d, J = 6.8 Hz, 3H), 1.06 (s, 9H), 1.07-1.46 (m, 
13H), 1.64 (m, 1H), 1.79 (m, 1H), 1.88-2.10 (m, 3H), 2.10 (dd, J = 8.0, 14.4 Hz, 1H), 2.30 
(dd, J = 6.0, 14.4 Hz, 1H), 3.44 (dd, J = 6.0, 10.0 Hz, 1H), 3.52 (dd, J = 6.0, 10.0 Hz, 1H), 
3.66 (s, 3H), 5.21 (dd, J = 7.6, 15.2 Hz, 1H), 5.31 (m, 1H), 7.36-7.44 (m, 6H), 7.66-7.69 













(q), 24.3 (t), 24.5 (t), 26.8 (q), 30.2 (d), 33.1 (d), 33.3 (t), 35.6 (d), 36.6 (t), 36.6 (d), 36.7 
(t), 37.0 (t), 39.8 (t), 41.6 (t), 51.2 (q), 68.8 (t), 126.9 (d), 127.4 (d), 129.3 (d), 134.0 (s), 
135.5 (d), 137.4 (d), 173.7 (s) ppm. MS(CI) for C37H58O3Si: m/z = 597 (M + NH4)+, HRMS 






en-1-ol (4.17): To a solution of 4.16 (100 mg, 0.173 mmol) in THF (6.0 mL) at -78 oC was 
added a solution of Dibal-H (20 wt% in toluene, 0.71 mL, 0.86 mmol, 5.0 eq) and the 
resulting mixture was stirred for 2 h at -78 oC under argon, after which TLC showed 
complete conversion. The reaction was quenched with aq. NH4Cl (sat.) and then diluted 
with Et2O and aq. HCl (1.0 M) until a clear solution was obtained. The aqueous layer was 
extracted with Et2O (3x) and the combined organic layers were washed with aq. NaHCO3 
(sat.) and brine (sat.), dried (Na2SO4) and concentrated. The product (4.17, 93 mg, 0.169 
mmol, 98%) was isolated as a colorless oil after column chromatography (n-pentane:EtOAc 
4:1). (3R,7S,11R,15S)-4.17: []D22 = +7.9o (c = 1.12, CHCl3),  1H-NMR (CDCl3, 400 MHz) 
 = 0.83 (d, J = 6.8 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H), 0.95 (d, J = 
6.8 Hz, 3H), 1.06 (s, 9H), 1.07-1.69 (m, 17H), 1.80 (m, 1H), 1.98 (m, 1H), 2.06 (m, 1H), 
3.41 (dd, J = 6.0, 10.0 Hz, 1H), 3.51 (dd, J = 6.0, 10.0 Hz, 1H), 3.67 (m, 2H), 5.22 (dd, J = 
7.6, 15.2 Hz, 1H), 5.32 (m, 1H), 7.36-7.44 (m, 6H), 7.66-7.68 (m, 4H) ppm. 13C-NMR 
(CDCl3, 100.6 MHz)  = 16.9 (q), 19.2 (s), 19.4 (q), 19.5 (q), 21.0 (q), 24.3 (t), 24.5 (t), 
26.8 (q), 29.3 (d), 33.1 (d), 33.3 (t), 35.6 (d), 36.69 (t), 36.71 (d), 37.0 (t), 37.3 (t), 39.87 (t), 
39.90 (t), 61.1 (t), 68.8 (t), 126.8 (d), 127.4 (d), 129.3 (d), 134.0 (s), 135.5 (d), 137.5 (d) 
ppm. MS(CI) for C36H58O2Si: m/z = 568 (M + NH4)+, HRMS calcd for C36H58O2Si-C4H9: 






enyl p-toluenesulfonate (4.18): 4.17 (90 mg, 0.16 mmol) was dissolved in dry pyridine 
(0.62 mL) and and p-TsCl (47 mg, 0.25 mmol, 1.5 eq) was added at 0 oC. The resulting 
solution was stirred at 0 oC under argon overnight and then quenched with water. The 
aqueous layer was extracted with Et2O (3x) and the combined organic layers were washed 
with aq. CuSO4 (sat.), aq. NaHCO3 (sat.) and brine (sat.), dried (MgSO4) and concentrated 
to give 4.18 (99 mg, 0.14 mmol, 86%) as a colorless oil after purification by column 
chromatography (n-pentane-EtOAc 95:5). (3R,7S,11R,15S)-4.18: []D22 = +7.9o (c = 1.46, 
CHCl3),  1H-NMR (CDCl3, 400 MHz)  = 0.78 (d, J = 6.4 Hz, 3H), 0.82 (d, J = 6.4 Hz, 
3H), 0.92 (t, J = 6.8 Hz, 6H), 1.05 (s, 9H), 1.06-1.70 (m, 17H), 1.78 (m, 1H), 2.00 (m, 2H), 
2.45 (s, 3H), 3.43 (dd, J = 6.4, 9.6 Hz, 1H), 3.51 (dd, J = 5.2, 9.6 Hz, 1H), 4.05 (m, 2H), 
5.20 (dd, J = 7.6, 15.2 Hz, 1H), 5.30 (m, 1H), 7.33-7.44 (m, 8H), 7.66-7.68 (dd, J = 1.6, 7.6 
Hz, 4H), 7.79 (d, J = 8.4 Hz, 2H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 16.9 (q), 19.0 
(q), 19.2 (s), 19.3 (q), 20.9 (q), 21.5 (q), 24.3 (t), 26.8 (q), 29.0 (d), 33.0 (d), 33.3 (t), 35.60 
(d), 35.63 (t), 36.5 (t), 36.6 (d), 36.7 (t), 37.1 (t), 39.8 (t), 68.8 (t), 69.0 (t), 126.9 (d), 127.4 
(d), 127.8 (d), 129.3 (d), 129.7 (d), 133.1 (s), 134.0 (s), 135.5 (d), 137.4 (d), 144.5 (s) ppm. 
  
 







MS(CI) for C43H64O4SSi: m/z = 722 (M + NH4)+, HRMS calcd for C43H64O4SSi-C4H9: 





(4.19): n-Pentyl bromide (0.50 mL, 4.0 mmol) in dry THF (9.5 mL) was added dropwise to 
Mg (147 mg, 6.05 mmol, 1.5 eq) in an argon-purged flask and then stirred for 1 h at 45 oC. 
The resulting solution was cooled to room temperature and the precipitate was allowed to 
settle overnight. Titration with sec-butanol in the presence of 1,10-phenanthroline showed 
the concentration of C5H11MgBr to be 0.43 M. The Grignard reagent (1.72 mL, 0.740 
mmol, 4.3 eq) was added in a dropwise fashion to a solution of 4.18 (120 mg, 0.171 mmol) 
and CuBrSMe2 (9.5 mg, 46 µmol, 27 mol%) in dry THF (1.6 mL) at -78 oC under argon. 
After stirring for 1 h at -78 oC, the solution was allowed to warm to 0 oC and stirred 
overnight. The reaction was quenched with aq. NH4Cl (sat.), extracted with Et2O (3x) and 
the combined organic layers were washed with brine (sat.), dried (MgSO4) and 
concentrated. 4.19 (101 mg, 0.167 mmol, 98%) was isolated as a colorless oil after 
purification by column chromatography (n-pentane). (2S,6R,10S,14S)-4.19: []D22 = +6.0o 
(c = 1.51, CHCl3),  1H-NMR (CDCl3, 400 MHz)  = 0.82-0.97 (m, 15H), 1.06 (s, 9H), 1.07 
(m, 4H), 1.14-1.46 (m, 22H), 1.65 (m, 1H), 1.80 (m, 1H), 1.94-2.12 (m, 2H), 3.43 (dd, J = 
6.0, 10.0 Hz, 1H), 3.51 (dd, J = 5.6, 10.0 Hz, 1H), 5.20-5.36 (m, 2H), 7.36-7.45 (m, 6H), 
7.66-7.70 (m, 4H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 14.0 (q), 16.9 (q), 19.2 (s), 19.4 
(q), 19.6 (q), 21.0 (q), 22.6 (t), 24.3 (t), 24.7 (t), 26.8 (q), 27.0 (t), 29.3 (t), 29.9 (t), 31.8 (t), 
32.6 (d), 33.1 (d), 33.3 (t), 35.6 (d), 36.70 (t), 36.72 (d), 37.0 (t), 37.4 (t), 39.9 (t), 68.8 (t), 
126.7 (d), 127.4 (d), 129.3 (d), 134.0 (s), 135.5 (d), 137.7 (d) ppm. MS(CI) for C41H68OSi: 
m/z = 623 (M + NH4)+, HRMS calcd for C41H68OSi-C4H9: 547.434, found: 547.434. 
tert-Butyl-diphenyl-((2S,6R,10S,14S)-2,6,10,14-tetramethyl-henicos-8-enyloxy)-silane 
(4.19) from 4.14 and 4.23: To a solution of 4.14 (964 mg, 1.59 mmol) and 4.23 (415 mg, 
1.83 mmol, 1.15 eq) in THF (19 mL) at -78 oC was added LiHMDS (1.0 M in THF, 1.67 
mL, 1.67 mmol, 1.05 eq) in a dropwise fashion over 5 min. The resulting yellow solution 
was stirred at -78 oC for 3 h and then allowed to warm to room temperature overnight. The 
reaction was quenched with aq. NH4Cl (sat.) and the aqueous layer was extracted with Et2O 
(3x). The combined organic layers were washed with brine (sat.), dried (MgSO4) and 
concentrated. Purification by column chromatography (n-pentane) gave 4.19 (713 mg, 1.18 
mmol, 74%) as a colorless oil. Analytical data are shown above. 
 
8-(tert-Butyl-diphenyl-silanyloxy)-(3R,7S)-3,7-dimethyl-octyl p-toluenesulfonate 
(4.20): 4.7 (1.96 g, 4.76 mmol) was dissolved in dry 
pyridine (17.7 mL) and p-TsCl (1.36 g, 7.13 mmol, 1.5 
eq) was added at 0 oC. The resulting solution was stirred 
at 0 oC under argon for 36 h and then quenched with water. The aqueous layer was 
extracted with Et2O (3x) and the combined organic layers were washed with aq. CuSO4 
(sat. 2x), aq. NaHCO3 (sat.) and brine (sat.), dried (MgSO4) and concentrated to give 4.20 
(2.33 g, 4.11 mmol, 86%) as a colorless oil after purification by column chromatography 












400 MHz)  = 0.79 (d, J = 6.4 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H), 1.06 (s, 9H), 1.06-1.52 (m, 
8H), 1.64 (m, 2H) 2.44 (s, 3H), 3.43 (dd, J = 6.4, 10.0 Hz, 1H), 3.50 (dd, J = 5.6, 10.0 Hz, 
1H), 4.06 (m, 2H), 7.32-7.44 (m, 8H), 7.66-7.68 (m, 4H), 7.80 (d, J = 8.4 Hz, 2H) ppm. 
13C-NMR (CDCl3, 100.6 MHz)  = 16.8 (q), 19.0 (q), 19.2 (s), 21.5 (q), 24.0 (t), 26.8 (q), 
29.1 (d), 33.2 (t), 35.5 (d), 35.6 (t), 36.8 (t), 68.7 (t) 69.0 (t), 127.4 (d), 127.8 (d), 129.4 (d), 
129.7 (d), 133.1 (s), 134.0 (s), 135.5 (d), 144.5 (s) ppm. MS(CI) for C33H46O4SSi: m/z = 
584 (M + NH4)+, HRMS calcd for C33H46O4SSi-C4H9: 509.218, found: 509.219. 
 
tert-Butyl-((2S,6S)-2,6-dimethyl-tridecyloxy)-diphenyl-silane (4.21): Pentyl bromide 
(2.50 mL, 20.2 mmol) in dry THF (47.5 mL) 
was added dropwise to Mg (735 mg, 30.2 mmol, 
1.5 eq) in an argon-purged flask and then stirred 
for 1 h at 45 oC. The resulting solution was cooled to room temperature and the precipitate 
was allowed to settle overnight. Titration with sec-butanol in the presence of 1,10-
phenanthroline showed the concentration of C5H11MgBr to be 0.39 M. The Grignard 
reagent (41.7 mL, 16.3 mmol, 4.0 eq) was added over 40 min to a solution of 4.20 (2.30 g, 
4.06 mmol) and CuBrSMe2 (209 mg, 1.02 mmol, 25 mol%) in dry THF (38 mL) at -78 oC 
under argon. After stirring for 2 h at -78 oC, the solution was allowed to warm to 0 oC and 
stirred overnight. The reaction was quenched with aq. NH4Cl (sat.), extracted with Et2O 
(3x) and the combined organic layers were washed with brine (sat.), dried (MgSO4) and 
concentrated. 4.21 (1.84 g, 3.94 mmol, 97%) was isolated as a colorless oil after 
purification by column chromatography (n-pentane). (2S,6S)-4.21: []D20 = -0.8o (c = 1.27, 
CHCl3),  1H-NMR (CDCl3, 400 MHz)  = 0.86 (d, J = 6.8 Hz, 3H), 0.92 (t, J = 7.2 Hz, 3H), 
0.96 (d, J = 6.8 Hz, 3H), 1.09 (s, 9H), 1.06-1.52 (m, 19H), 1.67 (m, 1H) 3.47 (dd, J = 6.4, 
9.6 Hz, 1H), 3.50 (dd, J = 5.6, 9.6 Hz, 1H), 7.38-7.46 (m, 6H), 7.70-7.72 (m, 4H) ppm. 13C-
NMR (CDCl3, 100.6 MHz)  = 14.0 (q), 16.9 (q), 19.2 (s), 19.6 (q), 22.6 (t), 24.3 (t), 26.8 
(q), 27.0 (t), 29.3 (t), 29.9 (t), 31.9 (t), 32.6 (d), 33.4 (t), 35.6 (d), 37.0 (t), 37.3 (t), 68.8 (t), 
127.4 (d), 129.4 (d), 134.1 (s), 135.5 (d) ppm. MS(CI) for C31H50OSi: m/z = 484 (M + 
NH4)+, HRMS calcd for C31H50OSi-C4H9: 409.293, found: 409.294. 
 
(2S,6S)-2,6-Dimethyl-tridecan-1-ol (4.22): TBAF (1.0 M in THF, 15.7 mL, 15.7 mmol, 
4.0 eq) was added to a solution of 4.21 (1.83 g, 3.92 
mmol) in THF (26.5 mL) and the resulting mixture 
was stirred for 2 h at room temperature, after which TLC showed complete conversion. The 
reaction was quenched with aq. NH4Cl (sat.), extracted with Et2O (3x) and the combined 
organic layers were washed with brine (sat.), dried (MgSO4) and concentrated. Because 
4.22 was difficult to separate from the TBDPS-waste products, the crude product was used 
in the next step. An analytical sample was purified by column chromatography 
(benzene:Et2O 95:5 and then a second column using n-pentane-Et2O 9:1 to 4:1) to give a 
colorless oil. (2S,6S)-4.22: []D22 = -8.0o (c = 1.05, CHCl3),  1H-NMR (CDCl3, 400 MHz)  
= 0.84 (d, J = 6.4 Hz, 3H), 0.87 (t, J = 6.8 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H), 1.07 (m, 3H), 
1.18-1.40 (m, 16H), 1.46 (brs, 1H), 1.61 (m, 1H), 3.40 (dd, J = 6.8, 10.4 Hz, 1H), 3.50 (dd, 
J = 5.6, 10.4 Hz, 1H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 14.0 (q), 16.5 (q), 19.6 (q), 
22.6 (t), 24.3 (t), 27.0 (t), 29.3 (t), 29.9 (t), 31.8 (t), 32.6 (d), 33.4 (t), 35.7 (d), 36.9 (t), 37.2 














(2S,6S)-2,6-Dimethyl-tridecanal (4.23): Crude 4.22 (3.92 mmol) was dissolved in dry 
dichloromethane (37 mL) in the presence of crushed 
molsieves (4Å) and stirred for 20 min. Subsequently, 
NMO-oxide (668 mg, 5.70 mmol, 1.50 eq) and TPAP 
(80 mg, 0.23 mmol, 0.06 eq) were added. The resulting black solution was stirred for 45 
min, after which TLC showed conversion into a single product. The reaction mixture was 
filtered over a silica plug (dichloromethane) and concentrated. After column 
chromatography (n-pentane-EtO2 98:2) 4.23 (639 mg, 2.82 mmol, 72% from 4.21) was 
obtained as a colorless liquid. Because the product was sensitive to oxidation, the pressure 
after concentration in vacuo was equalized with nitrogen instead of air and (2S,6S)-4.23 
was immediately used in the next step. 1H-NMR (CDCl3, 400 MHz)  = 0.84 (d, J = 6.4 Hz, 
3H), 0.88 (t, J = 6.8 Hz, 3H), 1.07 (m, 2H), 1.09 (d, J = 6.8 Hz, 3H), 1.18-1.40 (m, 16H), 
1.69 (m, 1H),  2.34 (ddd, J = 2.0, 6.8, 13.6 Hz, 1H) ppm. 13C-NMR (CDCl3, 50.32 MHz)  
= 13.3 (q), 14.0 (q), 19.5 (q), 22.6 (t), 24.3 (t), 26.9 (t), 29.3 (t), 29.8 (t), 30.8 (t), 31.8 (t), 
32.5 (d), 33.8 (t), 36.9 (t), 46.3 (d), 205.2 (d) ppm. MS(CI) for C15H30O+O (oxidized to 




(2S,6R,10S,14S)-2,6,10,14-Tetramethyl-henicos-8-en-1-ol (4.24): TBAF (1.0 M in THF, 
6.3 mL, 6.3 mmol, 4.0 eq) was added to a solution of 4.23 (958 mg, 1.58 mmol) in THF 
(10.6 mL) and the resulting mixture was stirred for 2 h, after which TLC showed complete 
conversion. The reaction was quenched with aq. NH4Cl (sat.), extracted with Et2O (3x) and 
the combined organic layers were washed with brine (sat.), dried (MgSO4) and 
concentrated. Because 4.24 was difficult to separate from the TBDPS-waste products, the 
crude product was used in the next step. An analytical sample was purified by column 
chromatography (benzene-Et2O 95:5) to give a colorless oil. (2S,6R,10S,14S)-4.24: []D22 = 
+6.1o (c = 1.06, CHCl3),  1H-NMR (CDCl3, 400 MHz)  = 0.83 (d, J = 7.2 Hz, 3H), 0.84 (d, 
J = 7.2 Hz, 3H), 0.88 (t, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.4 Hz, 3H), 
1.06 (m, 4H), 1.14-1.48 (m, 23H), 1.61 (m, 1H), 1.81 (m, 1H), 1.98 (m, 1H), 2.05 (m, 1H), 
3.41 (dd, J = 6.4, 10.0 Hz, 1H), 3.51 (dd, J = 5.6, 10.0 Hz, 1H), 5.22 (dd, J = 7.2, 15.2 Hz, 
1H), 5.31 (m, 1H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 14.0 (q), 16.5 (q), 19.4 (q), 19.6 
(q), 21.0 (q), 22.6 (t), 24.3 (t), 24.7 (t), 27.0 (t), 29.3 (t), 29.9 (t), 31.8 (t), 32.7 (d), 33.1 (d), 
33.3 (t), 35.7 (d), 36.65 (t), 36.72 (d), 37.0 (t), 37.4 (t), 39.9 (t), 68.3 (t), 126.6 (d), 137.8 (d) 




(2S,6R,10S,14S)-2,6,10,14-Tetramethyl-henicos-8-enal (4.25): Crude 4.24 (1.58 mmol) 
was dissolved in dry dichloromethane (15.4 mL) in the presence of crushed molsieves (4Å) 
and stirred for 20 min. Subsequently, NMO-oxide (278 mg, 2.37 mmol, 1.50 eq) and TPAP 
(33 mg, 0.10 mmol, 0.06 eq) were added. The resulting black solution was stirred for 30 
min, after which TLC showed conversion into a single product. The reaction mixture was 
filtered over a silica plug (dichloromethane) and concentrated. After column 











obtained as a colorless oil. Because the product was sensitive to oxidation, the pressure 
after concentration in vacuo was equalized with nitrogen instead of air and 4.25 was 
immediately used in the next step. 1H-NMR (CDCl3, 400 MHz)  = 0.82 (d, J = 6.4 Hz, 
3H), 0.84 (d, J = 6.8 Hz, 3H), 0.88 (t, J = 6.8 Hz, 3H), 0.95 (d, J = 6.4 Hz, 3H), 1.09 (d, J = 
6.8 Hz, 3H), 1.09 (m, 4H), 1.16-1.50 (m, 21H), 1.69 (m, 1H), 1.82 (m, 1H), 1.97 (m, 1H), 
2.05 (m, 1H), 2.33 (m, 1H), 5.20-5.34 (m, 2H), 9.61 (d, J = 2.0 Hz, 1H) ppm. 13C-NMR 
(CDCl3, 100.6 MHz)  = 13.2 (q), 14.0 (q), 19.3 (q), 19.6 (q), 21.0 (q), 22.6 (t), 24.3 (t), 
24.6 (t), 27.0 (t), 29.3 (t), 29.9 (t), 30.7 (t), 31.8 (t), 32.6 (d), 32.9 (d), 36.3 (t), 36.7 (d), 
37.0 (t), 37.4 (t), 39.8 (t), 46.2 (d), 126.4 (d), 137.9 (d) 205.3 (d) ppm. MS(EI) for C25H48O: 
m/z = 364 [M+], HRMS calcd for C25H48O: 364.371, found: 364.373. 
 
4-Benzyloxy-butan-1-ol (4.26): To a solution of butane-1,4-diol (4.95 mL, 55.5 mmol) in 
dry THF (36 mL) was added NaH (50%, 2.66 g, 55.5 mmol) at 0 oC. 
Subsequently, BnBr (6.60 mL, 55.5 mmol) in THF (12 mL) was added 
to the mixture and a small amount of DMF to increase solubility. The resulting suspension 
was stirred overnight under argon at room temperature, after which the reaction was 
quenched with aq. NH4Cl (sat.). The aqueous layer was extracted with Et2O (3x) and the 
combined organic layers were washed with brine (sat.), dried (MgSO4) and concentrated. 
The product was purified by column chromatography (n-pentane-EtOAc 4:1 to 7:3) to give 
4.26 (8.10 g, 44.9 mmol, 81%) as a light yellow oil. NMR-data were as reported in the 
literature.52 
 
3-Benzyloxy-propionaldehyde (4.27):52 To a solution of PCC (5.3 g, 24 mmol, 2.2 eq) in 
dichloromethane (38 mL) was added a solution of 4.26 (2.0 g, 11 mmol) 
in dichloromethane (6.8 mL). The resulting dark green mixture was 
stirred under argon overnight and then filtered over a silica plug (dichloromethane). After 
concentration, 4.27 (1.2 g, 6.7 mmol, 61%) was obtained as a colorless liquid, which was 
used without further purification. 1H-NMR (CDCl3, 400 MHz)  = 1.95 (m, 2H), 2.54 (dt, J 
= 1.6, 6.8, 14.4 Hz, 2H), 3.50 (t, J = 6.4 Hz, 2H), 4.49 (s, 2H), 7.24-7.37 (m, 5H), 9.77 (t, J 
= 1.6 Hz, 1H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 22.3 (t), 40.7 (t), 68.9 (t), 72.7 (t), 
127.4 (d), 128.1 (d), 138.0 (s), 202.0 (d) ppm.  
 
S-Ethyl (2E)-6-(benzyloxy)hex-2-enethioate (4.28): Preparation of the Wittig reagent:41 
Bromoacetic acid (13.9 g, 100 mmol), ethanethiol (9.65 mL, 130 
mmol) and DMAP (1.22 g, 10.0 mmol) were dissolved in 
dichloromethane (450 mL) and cooled to 0 oC. To the resulting 
mixture was added DCC (21.7 g, 105 mmol) in three equal portions, after which the 
solution was warmed to room temperature and stirred overnight under argon. The resulting 
white suspension was filtered over celite and the residue was washed with dichloromethane 
(3x). The filtrate was partially concentrated in vacuo and then washed with aq. NaHCO3 
(sat.), water and brine (sat.). The organic layer was dried (Na2SO4), filtered and 
concentrated to give a yellow oil, which was dissolved in benzene (150 mL). To this 
solution was added PPh3 (26.3 g, 100 mmol), after which the mixture was left to crystallize 
for 4 days. The crystals were filtered off and washed with cold toluene, after which they 
were dissolved in dichloromethane. The solution was washed with aq. Na2CO3 (10% w/w) 

















layers were dried (MgSO4), filtered and partially concentrated. The product was crystallized 
from a mixture of dichloromethane and n-pentane to give EtSC(O)C=PPh3 (25 g, 69 mmol, 
69%) as white/colorless crystals. 1H-NMR (CDCl3, 400 MHz)  = 1.25 (t, J = 7.6 Hz, 3H), 
2.84 (q, J = 7.6 Hz, 2H), 3.66 (d, J = 21.6 Hz, 1H), 7.44-7.65 (m, 15H) ppm. 
EtSC(O)C=PPh3 (1.21 g, 3.33 mmol, 1.1 eq) was added to a solution of 4.27 (540 mg, 3.03 
mmol) in chloroform (35 mL) and the resulting mixture was refluxed under argon for 3 h. 
The reaction mixture was cooled to room temperature and then stirred overnight in the 
presence of DMAP (100 mg, 0.82 mmol), after which the solvent was removed in vacuo. 
Trans-4.28 (more polar, 697 mg, 2.64 mmol, 87%) and a small amount of cis-4.28 (less 
polar) were obtained as colorless oils after purification by column chromatography (n-
pentane-EtOAc 95:5 to 9:1). 1H-NMR trans-4.28 (CDCl3, 400 MHz)  = 1.28 (t, J = 7.6 
Hz, 3H), 1.78 (m, 2H), 2.31 (m, 2H), 2.94 (q, J = 7.6 Hz, 2H), 3.49 (t, J = 6.4 Hz, 2H), 4.50 
(s, 2H), 6.11 (d, J = 15.2 Hz, 1H), 6.90 (dt, J = 7.2, 15.2 Hz, 1H) 7.26-7.37 (m, 5H) ppm. 
13C-NMR trans-4.28 (CDCl3, 100.6 MHz)  = 14.6 (q), 22.9 (t), 27.9 (t), 28.7 (t), 69.0 (t), 
72.8 (t), 127.42 (d), 127.44 (d), 128.2 (d), 128.8 (d), 138.2 (s), 144.3 (d) 189.9 (s) ppm. 
MS(EI) for C15H20O2S-C2H5: m/z = 235 [M+]. 
1H-NMR cis-4.28 (CDCl3, 400 MHz)  = 1.28 (t, J = 7.6 Hz, 3H), 1.78 (m, 2H), 2.74 (m, 
2H), 2.92 (q, J = 7.6 Hz, 2H), 3.50 (t, J = 6.4 Hz, 2H), 4.50 (s, 2H), 5.98-6.08 (m, 2H), 
7.26-7.36 (m, 5H) ppm. 13C-NMR cis-4.28 (CDCl3, 100.6 MHz)  = 14.6 (q), 23.1 (t), 26.7 
(t), 29.1 (t), 69.6 (t), 72.8 (t), 126.5 (d), 127.4 (d), 127.5 (d), 128.2 (d), 138.3 (s), 146.0 (d) 
189.7 (s) ppm. MS(EI) for C15H20O2S-C2H5S: m/z = 203 [M+]. 
 
S-Ethyl (3R)-6-(benzyloxy)-3-methylhexanethioate (4.29):33 (R,S)-Josiphos (L*, 67 mg, 
0.11 mmol, 6 mol%) and CuBr·SMe2 (19 mg, 0.094 mmol, 5 
mol%) were dissolved in tBuOMe (17 mL) and stirred for 30 min 
under argon at room temperature. The mixture was cooled to -78 
oC and MeMgBr (3.0 M in Et2O, 0.78 mL, 2.3 mmol, 1.3 eq) was added dropwise over 2 
min. After stirring for 10 min, a solution of trans-4.28 (495 mg, 1.87 mmol) in tBuOMe 
(1.9 mL) was added over 5 h by syringe pump and the resulting mixture was stirred 
overnight at -78 oC. The reaction was quenched with MeOH at -78 oC, removed from the 
cold bath and diluted with H2O, aq. NH4Cl (sat.) and Et2O. The product was extracted with 
Et2O (3x), the combined organic layers were washed with brine (sat.), dried (MgSO4) and 
concentrated. (3R)-4.29 (485 mg, 1.73 mmol, 92%, 93% ee) was isolated as a colorless 
liquid after purification by column chromatography (n-pentane-EtOAc 95:5). (3R)-4.29: 
[]D22 = +5.1o (c = 1.88, CHCl3), 1H-NMR (CDCl3, 400 MHz)  = 0.94 (d, J = 6.8 Hz, 3H), 
1.24 (t, J = 7.6 Hz, 3H), 1.22-1.31 (m, 1H), 1.41 (m, 1H), 1.63 (m, 2H), 1.94 (m, 1H), 2.36 
(dd, J = 8.4, 14.4 Hz, 1H), 2.54 (dd, J = 5.6, 14.4 Hz, 1H), 2.87 (q, J = 7.2 Hz, 2H), 3.45 (t, 
J = 6.4 Hz, 2H), 4.50 (s, 2H), 7.26-7.37 (m, 5H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 
14.7 (q), 19.3 (q) 23.2 (t), 27.0 (t), 30.8 (d), 32.9 (t), 51.2 (t), 70.3 (t), 72.8 (t), 127.4 (d), 
127.5 (d), 128.2 (d), 138.4 (s), 199.1 (s) ppm. MS(EI) for C16H24O2S: m/z = 280 [M+], 
HRMS calcd for C16H24O2S: 280.150, found: 280.149. Ee determination by chiral HPLC 
analysis, chiralcel OD-H column, n-heptane-iPrOH 99.5:0.5, retention times: 20.77 (R) / 













6-Benzyloxy-(3R)-3-methyl-hexan-1-ol (4.30): 4.29 (555 mg, 1.98 mmol) was dissolved 
in THF (6.0 mL) and LiAlH4 (188 mg, 4.95 mmol, 2.5 eq) was 
added at 0 oC. The resulting suspension was stirred for 45 min at 0 
oC under argon and then quenched with water. NaOH (3 M aq.) 
was added and the mixture was stirred until two clear layers were obtained. The layers were 
separated and the aqueous layer was extracted with Et2O (3x). The combined organic layers 
were washed with brine (sat.), dried (MgSO4) and concentrated. Purification by column 
chromatography (n-pentane-EtOAc 7:3) gave 4.30 (421 mg, 1.89 mmol, 96%) as a 
colorless liquid. (3R)-4.30: []D22 = +4.9o (c = 1.10, CHCl3), Lit. []D53 = +5.6o, 1H-NMR 
(CDCl3, 400 MHz)  = 0.90 (d, J = 6.8 Hz, 3H), 1.22 (m, 1H), 1.40 (m, 2H), 1.54-1.73 (m, 
3H), 3.46 (t, J = 6.4 Hz, 2H), 3.67 (m, 2H), 4.50 (s, 2H), 7.26-7.37 (m, 5H) ppm. 13C-NMR 
(CDCl3, 100.6 MHz)  = 19.4 (q), 27.0 (t), 29.2 (d), 33.3 (t), 39.7 (t), 61.0 (t), 70.6 (t), 72.8 
(t), 127.4 (d), 127.5 (d), 128.2 (d), 138.5 (s) ppm. MS(EI) for C14H22O2: m/z = 222 [M+], 
HRMS calcd for C14H22O2: 222.162, found: 222.164. 
 
5-(6-Benzyloxy-(3R)-3-methyl-hexylthio)-1-tert-butyl-1H-tetrazole (4.31): Preparation 
of 1-tert-butyl-1H-tetrazole-5-thiol:54 Sodium azide (5.64 g, 
86.8 mmol) was dissolved in water (27 mL) and heated 
under reflux, after which a solution of tert-
butylisothiocyanate (10.0 g, 86.8 mmol) in i-PrOH (21 mL) 
was added over 2 h. The resulting mixture was heated under 
reflux overnight and then cooled to 0 oC. Subsequently, concentrated aq. HCl (37%, 13 mL) 
was added and the solution was concentrated to 25-30 mL upon which a solid appeared. 
The suspension was stored at 0 oC for 5 h, after which the solid was filtered off. The residue 
was washed with ice-water and then crystallized from cyclohexane. The crystals were dried 
in vacuo at 50 oC for 5 h, after which recrystallization from cyclohexane afforded 1-tert-
butyl-1H-tetrazole-5-thiol (8.85 g, 55.9 mmol, 64.4%) as a mixture of yellow and white 
crystals. 
To a solution of PPh3 (779 mg, 2.96 mmol, 1.5 eq) and 4.30 (440 mg, 1.98 mmol) in THF 
(12.0 mL) at 0 oC was added DIAD (0.68 mL, 3.5 mmol, 1.8 eq) over 2 min resulting in a 
yellow suspension. Subsequently, a solution of 1-tert-butyl-1H-tetrazole-5-thiol (626 mg, 
3.96 mmol, 2.0 eq) in THF (6.0 mL) was added over 5 min and the reaction mixture was 
warmed to room temperature. After 1 h TLC showed complete conversion and the reaction 
was quenched with brine (sat.). The aqueous layer was extracted with Et2O (3x) and the 
combined organic layers were dried (MgSO4) and concentrated. Purification by column 
chromatography (n-pentane-EtOAc 9:1) gave 4.31 (610 mg, 1.68 mmol, 85%) as a 
colorless oil. (3R)-4.31: []D20 = -3.7o (c = 1.18, CHCl3), 1H-NMR (CDCl3, 400 MHz)  = 
0.95 (d, J = 6.0 Hz, 3H), 1.24 (m, 1H), 1.43 (m, 1H), 1.54-1.70 (m, 3H), 1.71 (s, 9H), 1.71-
1.86 (m, 2H), 3.31-3.50 (m, 2H), 3.45 (t, J = 6.4 Hz, 2H), 4.49 (s, 2H), 7.24-7.36 (m, 5H) 
ppm. 13C-NMR (CDCl3, 50.32 MHz)  = 19.0 (q), 27.0 (t), 28.5 (q), 31.8 (t), 32.1 (d), 32.8 
(t), 35.8 (t), 60.7 (s), 70.4 (t), 72.8 (t), 127.3 (d), 127.5 (d), 128.2 (d), 138.4 (s), 152.6 (s) 



















5-(6-Benzyloxy-(3R)-3-methyl-hexane-1-sulfonyl)-1-tert-butyl-1H-tetrazole (4.32): 4.31  
(610 mg, 1.68 mmol) was dissolved in dichloromethane 
(18.0 mL) and mCPBA (70%, 2.44 g, 9.90 mmol, 5.9 eq) 
was added at 0 oC. The resulting suspension was warmed to 
room temperature and stirred overnight. The reaction was 
quenched with aq. Na2S2O3 (10% w/w) and diluted with dichloromethane. The organic 
layer was washed with aq. Na2S2O3 (10% w/w, 3x; no more peroxides present) and the 
combined aqueous layers were subsequently extracted with dichloromethane (3x). The 
combined organic layers were washed with aq. NaHCO3 (sat. 3x) and brine (sat.), dried 
(MgSO4) and concentrated. The product was purified by column chromatography (n-
pentane-EtOAc 9:1) to give 4.32 (631 mg, 1.60 mmol, 95%) as a colorless oil. (3R)-4.32: 
[]D20 = -3.8o (c = 1.00, CHCl3), 1H-NMR (CDCl3, 400 MHz)  = 0.99 (d, J = 6.8 Hz, 3H), 
1.30 (m, 1H), 1.47 (m, 1H), 1.55-1.73 (m, 3H), 1.80 (m, 1H), 1.85 (s, 9H), 1.99 (m, 1H), 
3.47 (t, J = 6.4 Hz, 2H), 3.77 (ddd, J = 5.2, 10.8, 14.4 Hz, 1H), 3.84 (ddd, J = 5.2, 11.2, 
14.4 Hz, 1H), 4.50 (s, 2H), 7.26-7.37 (m, 5H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 
18.9 (q), 26.9 (t), 28.4 (t), 29.5 (q), 31.8 (d), 32.6 (t), 54.8 (t), 65.2 (s), 70.1 (t), 72.8 (t), 
127.4 (d), 127.5 (d), 128.2 (d), 138.3 (s), 153.8 (s) ppm. MS(EI) for C19H30N4O3S m/z = 





benzene (4.33): To a solution of 4.25 (455 mg, 1.25 mmol) and 4.32 (608 mg, 1.54 mmol, 
1.24 eq) in THF (19 mL) at -78 oC was added LiHMDS (1.0 M in THF, 1.41 mL, 1.41 
mmol, 1.13 eq) in a dropwise fashion over 5 min. The resulting yellow solution was stirred 
at -78 oC for 3 h and then allowed to warm to room temperature overnight. The reaction 
was quenched with aq. NH4Cl (sat.) and the aqueous layer was extracted with Et2O (3x). 
The combined organic layers were washed with brine (sat.), dried (MgSO4) and 
concentrated. Purification by column chromatography (n-pentane-Et2O 98:2) gave 4.33 
(549 mg, 0.99 mmol, 80%) as a colorless oil. (4R,8S,12R,16S,20S)-4.33: []D22 = +15.0o (c 
= 0.55, CHCl3), 1H-NMR (CDCl3, 400 MHz)  = 0.83 (d, J = 6.4 Hz, 6H), 0.87 (d, J = 6.4 
Hz, 3H),  0.89 (t, J = 6.8 Hz, 3H), 0.95 (d, J = 6.8 Hz, 6H), 1.00-1.50 (m, 29H), 1.63 (m, 
2H), 1.81 (m, 2H), 1.93-2.09 (m, 4H), 3.45 (t, J = 6.8 Hz, 2H), 4.51 (s, 2H), 5.19-5.35 (m, 
4H), 7.25-7.37 (m, 5H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 14.0 (q), 19.3 (q), 19.4 
(q), 19.6 (q), 20.9 (q), 21.0 (q), 22.6 (t), 24.66 (t), 24.68 (t), 27.0 (t), 27.2 (t), 29.3 (t), 29.9 
(t), 31.8 (t), 32.6 (d), 32.7 (t), 33.0 (d), 33.1 (d), 36.5 (t), 36.69 (d), 36.73 (d), 37.03 (t), 
37.04 (t), 37.3 (t), 37.4 (t), 39.9 (t), 40.0 (t), 70.8 (t), 72.8 (t), 126.5 (d), 126.8 (d), 127.3 
(d), 127.5 (d), 128.2 (d), 137.7 (d), 137.8 (d), 138.6 (s) ppm. MS(EI) for C39H68O m/z = 




(4S,8S,12S,16S,20S)-4,8,12,16,20-Pentamethyl-heptacosan-1-ol (4.34): 4.33 (549 mg, 
0.99 mmol) was dissolved in EtOAc (50 mL) and Pd/C (10%, 750 mg) was added. The 

















by 5 vacuum-H2 cycles. After stirring overnight under an H2-atmosphere (1 bar), TLC 
showed complete conversion. The Pd/C was removed by filtration over a Florisil-plug and 
the resulting clear solution was concentrated in vacuo. After purification by column 
chromatography (n-pentane-EtOAc 9:1 to 9:2) 4.34 (381 mg, 0.82 mmol, 83%) was 
isolated as a colorless oil. (4S,8S,12S,16S,20S)-4.34: []D22 = -0.8o (c = 1.16, CHCl3), 1H-
NMR (CDCl3, 400 MHz)  = 0.84-0.90 (m, 18H), 1.00-1.42 (m, 44H), 1.57 (m, 2H), 3.63 
(t, J = 6.8 Hz, 2H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 14.0 (q), 19.6 (q), 19.7 (q), 
22.6 (t), 24.4 (t), 27.0 (t), 29.3 (t), 29.9 (t), 30.3 (t), 31.8 (t), 32.5 (d), 32.7 (d), 32.8 (t), 37.0 
(t), 37.3 (t), 63.4 (t) ppm. MS(EI) for C32H66O-H2O m/z = 448 [M+], MS(CI) for C32H66O: 
m/z = 484 (M + NH4)+, HRMS calcd for C32H66O-H2O: 448.501, found: 448.501. GC-
characterization: HP1-kolom, 30 m x 0.25 mm, He-flow = 1.0 mL/min, Ti = 70 oC for 70 
min, Tf = 300 oC, rate 10 oC/min, rt. 79.8 min (1 peak only). 
 
Benzyl 2-cyanoethyl N,N-Diisopropylphosphoramidite (4.35):2 Hunig’s base (EtN(iPr)2, 
1.47 mL, 8.44 mmol) was added to benzyl alcohol (0.44 mL, 4.27 
mmol) and after stirring for 5 min, 2-cyanoethyl N,N-
diisopropylchlorophosphoramidite (1.0 g, 4.23 mmol) was added. 
The resulting mixture was stirred for 1 h at room temperature and 
was then diluted with dichloromethane and aq. NaHCO3 (sat.). The 
aqueous layer was extracted with dichloromethane (2x) and the combined organic layers 
were dried (Na2SO4), filtered and concentrated. Purification by column chromatography (n-
pentane-Et2O-Et3N 80:20:1) furnished 4.35 (829 mg, 2.69 mmol, 64%) as a colorless liquid. 
NMR-data were as reported in the literature:2 1H-NMR (CDCl3, 400 MHz)  = 1.20 (t, J = 
7.2 Hz, 12H), 2.62 (t, J = 6.4 Hz, 2H), 3.66 (m, 2H), 3.85 (m, 2H), 4.67 (dd, J = 8.8, 12.4 










heptacosylphosphate (4.36): To an emulsion of 4.34 (76 mg, 0.16 mmol) and 4.35 (60 mg, 
0.20 mmol, 1.2 eq) in acetonitrile (0.83 mL) was added 1H-tetrazole (34 mg, 0.49 mmol, 
3.0 eq) and the resulting mixture was stirred for 1.5 h. Subsequently, tert- 
butylhydroperoxide (5.0-6.0 M in decane, 0.16 mL, 0.80-0.96 mmol, 5.0-6.0 eq) was added 
in a dropwise fashion and stirring was continued for 1 h. The resulting clear solution was 
concentrated in vacuo and 4.36 (104 mg, 0.15 mmol, 92%) was obtained as a colorless oil 
after purification by column chromatography (n-pentane-EtOAc 4:1 to 2:1 to 1:1). 
(4S,8S,12S,16S,20S)-4.36: []D22 = -0.2o (c = 1.03, CHCl3), 1H-NMR (CDCl3, 400 MHz)  
= 0.81-0.90 (m, 18H), 1.00-1.42 (m, 43H), 1.65 (m, 2H), 2.66 (dt, J = 2.8, 6.4 Hz, 2H), 3.03 
(q, J  = 6.8 Hz, 2H), 4.15 (m, 2H), 5.10 (d, J = 9.2 Hz, 2H), 7.35-7.40 (m, 5H) ppm. 13C-
NMR (CDCl3, 100.6 MHz)  = 14.0 (q), 19.3-19.6 (q + t), 22.6 (t), 24.4 (t), 27.0 (t), 27.6 
(t), 27.7 (t), 29.3 (t), 29.9 (t), 31.8 (t), 32.3 (d), 32.4 (t), 32.6-32.7 (d), 36.9-37.3 (t), 61.4 (t, 
JC-P = 4.6 Hz), 68.8 (t, J = 6.9 Hz), 69.6 (t, JC-P = 5.3 Hz), 128.0 (d), 128.6 (d), 128.7 (d), 























heptacosylphosphate (4.37): To a solution of 4.36 (96 mg, 0.14 mmol) in dichloromethane 
(0.56 mL) was added a solution of tetra-n-butylammonium hydroxide (54 mg, 0.21 mmol, 
1.5 eq) in water (0.56 mL) and the resulting mixture was stirred vigorously for 1 h. The 
reaction mixture was diluted with dichloromethane and water and the aqueous layer was 
extracted with dichloromethane (2x). The combined organic layers were dried (Na2SO4), 
filtered and concentrated to give 4.37 (122 mg, quantitative) as a yellow oil. 1H-NMR 
(CDCl3, 400 MHz)  = 0.76-0.86 (m, 18H), 0.93 (t, J =7.2 Hz, 12H), 0.93-1.42 (m, 51H), 
1.59 (m, 10H), 3.30 (m, 8H), 3.79 (q, J = 6.4 Hz, 2H), 4.91 (d, J = 6.0 Hz, 2H), 7.14-7.40 
(m, 5H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 13.5 (q), 14.0 (q), 19.3-19.6 (q + t), 22.5 
(t), 23.9 (t), 24.3 (t), 26.9 (t), 28.4 (t), 28.5 (t), 29.2 (t), 29.8 (t), 31.7 (t), 32.58 (d), 32.61 









Prepared as described for the synthesis of 4.37. The alcohol was obtained from commercial 
phytol via hydrogenation over PtO2.30g NMR-data were as reported in the literature: 1H-
NMR (CDCl3, 400 MHz)  = 0.80-0.86 (m, 15H), 0.97 (t, J =7.2 Hz, 12H), 0.95-1.43 (m, 
28H), 1.51 (m, 2H), 1.62 (m, 10H), 3.33 (m, 8H), 3.86 (m, 2H), 4.93 (d, J = 6.4 Hz, 2H), 
7.14-7.45 (m, 5H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 13.6, 19.5-19.6, 22.5, 22.6, 













D-mannopyranoside (4.39):2,30g To a solution of 4.3 (152 mg, 0.27 mmol) and 2,6-di-tert-
butyl-4-methylpyridine (DTBMP, 56 mg, 0.27 mmol) in toluene (11 mL) at -78 oC was 
added Tf2O (55 l, 0.33 mmol, 1.2 eq) in a dropwise fashion. The resulting mixture was 
stirred for 15 min under argon, after which a solution of 4.38 (581 mg, 0.82 mmol, 3.0 eq) 
in toluene (2.7 mL) was added. The mixture was stirred at -78 oC for 6 h and then quenched 
at this temperature with aq. NaHCO3 (sat.). After warming to room temperature, the 
aqueous layer was extracted with EtOAc (2x) and the combined organic layers were 
washed with brine (sat.), dried (MgSO4), filtered and concentrated. Because 4.39 was 
difficult to separate from the hydrolysis product of 4.3, the crude product was dissolved in 
pyridine (1.8 mL), after which  Ac2O (0.2 mL) was added. The mixture was stirred 
overnight and then concentrated in vacuo. The remaining oil was dissolved in EtOAc and 










dried (MgSO4), filtered and concentrated. Purification by column chromatography (n-
pentane-EtOAc 4:1 to 2:1) gave 4.39 (72 mg, 0.10 mmol, 37%, mixture of two 
diastereomers at P) as a yellow oil. NMR-data were as reported in the literature: 1H-NMR 
(CDCl3, 400 MHz)  = 0.78-0.90 (m, 15H), 0.99-1.50 (m, 21H), 1.51 (m, 2H), 1.68 (m, 
1H), 3.40 (m, 1H), 3.63 (2dd, J = 2.8, 10.0 Hz for both isomers, 1H), 3.81-4.15 (m, 4H), 
4.20 (t, J = 9.6 Hz, 1H), 4.29 (dd, J = 4.8, 10.4 Hz, 1H), 4.61 + 4.62 (2d, isomer 1 J = 12.4 
Hz, isomer 2 J = 12.0 Hz, 1H), 4.73 (d, J = 12.4 Hz, 1H), 4.77 (s, 1H), 4.89 (m, 1H), 5.05 
(d, J = 8.0 Hz, 1H), 5.08 (m, 1H), 5.24 (brt, J = 6.8 Hz, 1H), 5.59 + 5.60 (2s, one for each 
isomer, 1H), 7.26-7.54 (m, 20H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 19.1, 19.2, 19.5, 
19.6, 22.5, 22.6, 24.2, 24.4, 24.7, 27.8, 29.15, 29.18, 29.6, 32.7, 36.8-37.4, 39.2, 66.7, 
66.77, 66.84, 66.9, 67.8, 68.0, 68.1, 69.2, 69.3, 69.38, 69.44, 69.9, 72.6, 75.1, 75.2, 76.3, 














benzyl-4,6-benzylidene--D-mannopyranoside (4.40): Sulfon 4.3 (36 mg, 64 mol) was 
coupled to phosphate salt 4.37 (127 mg, 0.14 mmol, 2.3 eq) using DTBMP (13 mg, 64 
mol) and Tf2O (12 l, 71 mol, 1.1 eq) in toluene (2.5 + 0.5 mL) to yield 4.40 (7.0 mg, 6.6 
mol, 10%, mixture of two diastereomers at P). The reaction was performed as described 
for the preparation of 4.39. 1H-NMR (CDCl3, 400 MHz)  = 0.74-0.90 (m, 18H), 0.96-1.44 
(m, 43H), 1.64 (m, 2H), 3.34-3.51 (m, 1H), 3.63 (m, 1H), 3.70-4.41 (m, 6H), 4.61 (m, 1H), 
4.70 (m, 1H), 4.80 (m, 1H), 4.90 (m, 1H), 5.07 (m, 2H), 5.25 (m, 1H), 5.63 (s, 1H), 7.23-
7.54 (m, 20H) ppm. 
 
Diphenyl-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyl)-phosphate (-4.41):44 To a 
solution of 2,3,4,6-tetra-O-acetyl-D-mannopyranose (1.90 g, 
5.46 mmol) and DMAP (1.52 g, 12.4 mmol, 2.28 eq) in 
dichloromethane (32 mL) at room temperature was added a 
solution of diphenyl chlorophosphate (2.66 mL, 12.8 mmol, 
2.35 eq) in dichloromethane (13 mL) by syringe pump over 1 
h. After stirring the resulting solution under argon for 2 h, the 
reaction mixture was diluted with dichloromethane and washed with cold water, cold aq. 
HCl (0.5 M) and cold aq. NaHCO3 (sat.). The organic layer was dried (MgSO4), filtered and 
concentrated to give 4.41 (2.50 g, 4.31 mmol, 79%) as a mixture of anomers (ratio : = 
1:4). The pure -anomer of 4.41 (0.98 g, 1.69 mmol, 31%) was obtained after purification 
by column chromatography (n-pentane-EtOAc 8:3 to 3:2) together with a mixed fraction of 
anomers (1.40 g, 2.41 mmol, 44%). -4.41 was stable in solution at room temperature (even 
in chloroform) and for several months at -18oC when concentrated. However, when stored 
at room temperature after concentration, we observed that the fraction of -anomer 
increased either by epimerization or by selective degradation of the -anomer. 1H-NMR -
4.41 (CDCl3, 400 MHz)  = 1.94 (s, 3H, Ac), 2.00 (s, 6H, Ac), 2.05 (s, 3H, Ac), 3.77 (m, 




















5.07 (dd, J = 3.6, 9.6 Hz, 1H, C3-H), 5.22 (t, J = 9.6 Hz, 1H, C4-H), 5.46 (d, J = 3.2 Hz, 
1H, C2-H), 5.61 (d, J = 6.8 Hz, 1H, C1-H), 7.12-7.32 (m, 10H) ppm. 13C-NMR (CDCl3, 
100.6 MHz)  = 20.2 (q), 20.3 (q), 20.37 (q), 20.38 (q), 61.7 (t), 65.0 (d), 67.8 (d, JC-P = 8.5 
Hz), 69.8 (d), 72.7 (d), 94.5 (d,  JC-P = 4.6 Hz), 120.0 (d, JC-P = 4.5 Hz), 120.1 (d, JC-P = 4.5 
Hz), 125.4 (d), 125.6 (d), 129.4 (d), 129.6 (d), 149.7 (s, JC-P = 7.6 Hz), 150.1 (s, JC-P = 8.5 
Hz), 169.3 (s), 169.4 (s), 169.5 (s) 170.3 (s) ppm. 
 
Diphenyl-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyl)-phosphate (-4.41):44 A 
solution of DMAP (0.80 g, 6.6 mmol, 2.3 eq) and diphenyl 
chlorophosphate (1.4 mL, 6.8 mmol) in dichloromethane (6.7 
mL) was added over 30 min to a solution of 2,3,4,6-tetra-O-
acetyl-D-mannopyranose (1.00 g, 2.87 mmol) in 
dichloromethane (16.7 mL) at -30 oC. The resulting mixture was 
stirred under argon for 1 h at -30 oC and then maintained for 2 h 
between -10 and 0 oC. Work-up and purification was performed as described for -4.41  to 
give -4.41 (1.09 g, 1.88 mmol, 65%) as a colorless oil. 1H-NMR (CDCl3, 400 MHz)  = 
1.95 (s, 3H, Ac), 1.98 (s, 3H, Ac), 2.02 (s, 3H, Ac), 2.13 (s, 3H, Ac), 3.89 (dd, J = 2.0, 12.4 
Hz, 1H, C6-H), 4.05 (m, 1H, C5-H), 4.16 (dd, J = 4.8, 12.4 Hz, C6-H'), 5.23-5.37 (m, 3H, 
C2-H, C3-H and C4-H), 5.85 (dd, J = 2.0, 6.8, 1H, C1-H), 7.18-7.37 (m, 10H) ppm. 13C-
NMR (CDCl3, 100.6 MHz)  = 20.30 (q), 20.31 (q), 20.36 (q), 20.41 (q), 61.4 (t), 64.8 (d), 
67.9 (d), 68.4 (d, JC-P = 12.3 Hz), 70.5 (d), 95.9 (d, JC-P = 5.3 Hz), 119.8 (d, JC-P = 4.6 Hz), 
120.0 (d, JC-P = 4.5 Hz), 125.6 (d), 125.7 (d), 129.7 (d), 129.8 (d), 149.8 (s, JC-P = 6.9 Hz), 
150.0 (s, JC-P = 6.8 Hz), 169.3 (s), 169.5 (s), 170.3 (s) ppm. 
 
Pyridinium (2,3,4,6-tetra-O-acetyl--D-mannopyranosyl)-phosphate (-4.42): -4.41 
(667 mg, 1.15 mmol) was dissolved in EtOH-EtOAc (14,4 mL, 
1:1 v/v) and PtO2 (29 mg, 0.13 mmol, 0.11 eq) was added. The 
resulting suspension was degassed with 3 vacuum-argon cycles 
and then saturated with H2  by 5 vacuum-H2 cycles. After 
stirring over for 60 h under an H2-atmosphere (1 bar), TLC 
(chloroform/MeOH/water 60/35/6 v/v/v) showed complete conversion. The catalyst was 
removed by filtration over celite and the solution was neutralized with pyridine. After 
concentration -4.41 (469 mg, 0.92 mmol, 80%) was isolated as a white foam. 1H-NMR 
(D2O, 400 MHz)  = 1.88 (s, 3H, Ac), 1.96 (s, 3H, Ac), 1.99 (s, 3H, Ac), 2.10 (s, 3H, Ac), 
3.93 (ddd, J = 2.0, 3.6, 10.0 Hz, 1H, C5-H), 4.07 (dd, J = 2.0, 12.8 Hz, 1H, C6-H), 4.31 
(ddd, J = 3.6, 12.8 Hz, 1H, C6-H'), 5.09 (t, J = 10.0 Hz, 1H, C4-H), 5.21 (dd, J = 3.2, 10.4 
Hz, 1H, C3-H), 5.33 (dd, J = 0.8, 8.8 Hz, 1H, C1-H), 5.40 (d, J = 2.8 Hz, 1H, C2-H), 7.95 
(t, J = 7.2 Hz, 2H, Py), 8.50 (m, 1H, Py), 8.65 (d, J = 5.2 Hz, 2H, Py) ppm. 13C-NMR (D2O, 
50.32 MHz)  = 18.6 (q), 60.3 (t), 64.0 (d), 68.5 (d, JC-P = 6.8 Hz), 69.6 (d), 70.3 (d), 91.8 
(d), 125.9 (d), 171.1 (s), 171.6 (s), 171.7 (s), 172.2 (s) ppm. Positive ion ESI-HRMS calcd 






























Pyridinium (2,3,4,6-tetra-O-acetyl--D-mannopyranosyl)-phosphate (-4.42): -4.41 
(1.0 g, 1.7 mmol) was converted into -4.42 (831 mg, 1.64 
mmol, 95%) using a procedure analogous to the synthesis of -
4.42. 1H-NMR (D2O, 400 MHz)  = 1.92 (s, 3H, Ac), 2.00 (s, 3H, 
Ac), 2.03 (s, 3H, Ac), 2.10 (s, 3H, Ac), 4.07 (d, J = 12.8, 1H, C6-
H), 4.28 (d, J = 10.0 Hz, 1H, C5-H), 4.36 (dd, J = 2.8, 12.8 Hz, 
1H, C6-H'), 5.20 (t, J = 10.0 Hz, 1H, C4-H), 5.23 (brs,1H, C2-
H), 5.32 (dd, J = 3.2, 10.0 Hz, 1H), 5.40 (d, J = 8.0 Hz, 1H, C1-H), 7.99 (t, J = 7.2 Hz, 2H, 
Py), 8.50 (m, 1H, Py), 8.69 (d, J = 5.6 Hz, 2H, Py) ppm. 13C-NMR (D2O, 50.32 MHz)  = 
18.6 (q), 60.4 (t), 64.0 (d), 67.3 (d), 67.9 (d), 68.3 (d, JC-P = 10.3 Hz), 91.6 (d, J = 4.6 Hz), 















acetyl--D-mannopyranoside (-4.43): -4.42 (129 mg, 0.25 mmol, 2.0 eq) was brought 
into a dry two-neck flask (50 mL) and co-evaporated with freshly distilled dry toluene (2x; 
pressure equalized with nitrogen). Subsequently a solution of 4.34 (59 mg, 0.13 mmol) in 
dry toluene was added and the mixture was co-evaporated with dry toluene (2x). Finally 
TPSCl (115 mg, 0.38 mmol, 3.0 eq) was added and after two more additions and 
evaporations of dry toluene, the residue was dissolved in dry pyridine (2.7 mL) and stirred 
under argon for 4 days. The reaction was quenched with MeOH (2.5 mL) and stirred for 2 
more h before concentration (co-evaporation with toluene). The residue was dissolved in 
chloroform and washed with water (3x) and brine (sat.), dried (MgSO4), filtered and 
concentrated. The product was purified by column chromatography (chloroform-MeOH 
95:5 to 85:15) giving -4.43 (90 mg, 0.10 mmol, 79%) as a white foam. 
(4S,8S,12S,16S,20S)--4.43: []D22 = -9.7o (c = 1.22, CHCl3), 1H-NMR (CD3OD + 1 drop 
of CDCl3, 400 MHz)  = 0.82-0.92 (m, 18H), 1.03-1.46 (m, 43H), 1.61 (m, 2H), 1.95 (s, 
3H, Ac), 2.04 (s, 3H, Ac), 2.06 (s, 3H, Ac), 2.16 (s, 3H, Ac), 3.86 (m, 3H, C5-H and CH2-
OP), 4.16 (dd, J = 2.4, 12.4 Hz, 1H, C6-H), 4.28 (dd, J = 4.4, 12.0 Hz, 1H, C6-H'), 5.17-
5.25 (m, 2H, C3-H, C4-H), 5.42 (d, J = 8.8 Hz, 1H, C1-H), 5.48 (brs, 1H, C2-H) ppm. 13C-
NMR (CDCl3-CD3OD 1:1 (v/v), 100.6 MHz)  = 14.3 (q), 19.7-20.0 (q), 20.7 (q), 20.8 (q), 
23.0 (t), 24.8-24.9 (t), 27.4 (t), 28.5 (t), 28.6 (t), 29.7 (t), 30.3 (t), 32.3 (t), 33.1-33.2 (d), 
33.4 (t), 33.5 (t), 37.4 (t), 37.5 (t), 37.8-37.9 (t), 62.6 (t), 66.0 (d), 67.1 (t), 70.1 (d, JC-P = 
6.1 Hz), 71.5 (d), 72.8 (d), 94.0 (d), 170.5 (s), 170.6 (s), 171.2 (s), 171.5 (s) ppm. 31P-NMR 
(CDCl3-CD3OD 1:1 (v/v), 161.6 MHz)  = -5.6 ppm. Positive ion ESI-HRMS calcd for 































acetyl--D-mannopyranoside (-4.43): -4.42 (110 mg, 0.21 mmol, 2.0 eq) was coupled 
to 4.34 (50 mg, 0.11 mg, 1.0 eq) in the presence of TPSCl (98 mg, 0.32 mmol, 3.0 eq) to 
give -4.43 (49 mg, 56 mol, 52%) using a procedure analogous to the synthesis of -4.43. 
1H-NMR (CD3OD + 1 drop of CDCl3, 400 MHz)  = 0.82-0.92 (m, 18H), 1.03-1.46 (m, 
43H), 1.61 (m, 2H), 1.96 (s, 3H, Ac), 2.04 (s, 3H, Ac), 2.07 (s, 3H, Ac), 2.15 (s, 3H, Ac), 
3.89 (m, 2H, CH2-OP), 4.11 (dd, J = 2.4, 12.0 Hz, 1H, C6-H), 4.22 (m, 1H, C5-H), 4.29 
(dd, J = 4.0, 12.4 Hz, 1H, C6-H'), 5.28-5.37 (m, 3H, C2-H, C3-H and C4-H), 5.49 (d, J = 
6.8 Hz, 1H, C1-H) ppm. 13C-NMR (CDCl3-CD3OD 1:1 (v/v), 100.6 MHz)  = 14.5 (q), 
20.0-20.3 (q), 20.7 (q), 20.81 (q), 20.85 (q), 23.4 (t), 25.2-25.3 (t), 27.8 (t), 29.1 (t), 29.2 (t), 
30.2 (t), 30.7 (t), 32.7 (t), 33.5-33.6 (d), 33.9 (t), 37.8 (t), 37.9 (t), 38.15-38.23 (t), 63.1 (t), 
66.5 (d), 67.4 (t), 70.0 (d), 70.3 (d), 70.6 (d, JC-P = 9.2 Hz), 94.5 (d), 170.99 (s), 171.02 (s), 
171.1 (s), 171.9 (s) ppm. 31P-NMR (CDCl3-CD3OD 1:1 (v/v), 161.6 MHz)  = -5.8 ppm. 














mannopyranoside (-4.1): -4.43 (130 mg, 0.15 mmol) was dissolved in chloroform-
MeOH (3.5 mL, 1:2.5 v/v) and NaOMe was added (14 mg). The resulting solution was 
stirred for 60 min and then diluted with 1-butanol (30 mL) and quenched with aq. NH4Cl 
(sat. 20 mL). The organic layer was washed with water (3 x 20 mL) and then concentrated 
by co-evaporation with toluene. The resulting solid was placed on a pad of Celite and 
washed with acetone (50 mL) and then chloroform-MeOH (70 mL, 1:1 v/v). The 
chloroform-MeOH extract was concentrated to give -4.1 (108 mg, 0.15 mmol, 
quantitative) as a white solid. (4S,8S,12S,16S,20S)--4.1: []D22 = -3.6o (c = 0.55, CHCl3-
CH3OH-H2O 95:95:10 v/v/v), mp = 125 oC (decomp.), 1H-NMR (CD3OD-CDCl3-D2O 
0.45:0.45:0.05 (v/v/v), 400 MHz)  = 0.82-0.88 (m, 18H), 1.00-1.42 (m, 43H), 1.61 (m, 
2H), 3.28-3.32 (m, 1H, C5-H), 3.52-3.59 (m, 2H, C3-H and C4-H), 3.73 (dd, J = 5.6, 12.0 
Hz, 1H, C6-H), 3.82-3.88 (m, 3H, C6-H' and CH2-OP), 3.93 (d, J = 2.4 Hz, 1H, C2-H), 
5.07 (d, J = 8.0 Hz, 1H, C1-H) ppm. 13C-NMR (CD3OD-CDCl3-D2O 0.45:0.45:0.05 
(v/v/v),125.7 MHz)  = 14.5 (q), 19.9 (q), 20.2-20.3 (q), 23.3 (t), 25.0 (t), 25.1 (t), 25.2 (t), 
25.3 (t), 27.7 (t), 28.96 (t), 29.02 (t), 30.0 (t), 30.6 (t), 32.6 (t), 33.3-33.5 (d), 33.8 (t), 33.9 
(t), 37.6 (t), 37.7 (t), 38.0-38.2 (t), 61.8 (t), 67.3 (d) 67.4 (t, JC-P = 6.2 Hz), 72.1 (d), 74.0 
(d), 77.9 (d), 96.3 (d) ppm. 31P-NMR (CD3OD-CDCl3-D2O 0.45:0.45:0.05 (v/v/v),161.6 























mannopyranoside (-4.1): -4.43 (42 mg, 48 mol) was converted into -4.1 (35 mg, 48 
mol, quantitative) as described for the preparation of -4.1. 1H-NMR (CD3OD-CDCl3-
D2O 0.45:0.45:0.05 (v/v/v), 400 MHz)  = 0.82-0.88 (m, 18H), 0.98-1.42 (m, 43H), 1.61 
(m, 2H), 3.58-3.65 (m, 2H), 3.71 (dd, J = 5.6, 11.2 Hz, 1H, C6-H), 3.75-3.85 (m, 4H), 3.90 
(m, 1H) 5.38 (dd, J = 1.6, 7.6 Hz, 1H, C1-H) ppm. 13C-NMR (CD3OD-CDCl3-D2O 
0.45:0.45:0.05 (v/v/v),125.7 MHz)  = 14.4 (q), 14.5 (q), 19.8 (q), 19.9 (q), 20.1-20.3 (q), 
23.3 (t), 25.0 (t), 25.1-25.3 (t), 27.6 (t), 28.9 (t), 29.0 (t), 30.0 (t), 30.5 (t), 32.5 (t), 33.3-
33.4 (d), 33.7 (t), 33.8 (t), 37.6 (t), 37.7 (t), 38.0 (t), 61.7 (t), 67.1 (t, JC-P = 5.3 Hz), 67.5 
(d), 71.0 (d), 71.6 (d, JC-P = 8.4 Hz), 74.5 (d), 77.9 (d), 96.6 (d, JC-P = 5.4 Hz) ppm. 31P-
NMR (CD3OD-CDCl3-D2O 0.45:0.45:0.05 (v/v/v),161.6 MHz)  = -1.8 ppm. Negative ion 








(4S,8S,12S,16S,20S)-4,8,12,16,20-Pentamethylheptacosyl diphenyl phosphate (4.44): 
DMAP (30 mg, 0.25 mmol, 2.3 eq) was added to a solution of 4.34 (50 mg, 0.11 mmol) in 
dichloromethane (0.63 mL) and the resulting mixture was cooled to 0 oC. Subsequently, a 
solution of diphenyl chlorophosphate (51 l, 0.25 mmol, 2.3 eq) in dichloromethane (0.26 
mL) was added over 5 min. The solution was allowed to warm to room temperature and 
stirred overnight. The reaction mixture was diluted with dichloromethane and then washed 
with water, aq. HCl (1.0 M), aq. NaHCO3 (sat.) and brine (sat.). The organic layer was 
dried (MgSO4), filtered and concentrated. Purification by column chromatography (n-
pentane-EtOAc 95:5 to 92.5:7.5) yielded 4.44 (75 mg, 0.11 mmol, quantitative) as a 
colorless oil. 1H-NMR (CDCl3, 400 MHz)  = 0.81-0.95 (m, 18H), 1.01-1.44 (m, 43H), 
1.71 (m, 2H), 4.25 (q, J = 6.8 Hz, 2H), 7.19 (t, J = 7.2 Hz, 1H), 7.25 (m, 2H), 7.35 (m, 2H) 
ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 14.0 (q), 19.4 (q), 19.6 (q), 22.6 (t), 24.3 (t), 24.4 
(t), 27.0 (t), 27.65 (t), 27.72 (t), 29.3 (t), 29.9 (t), 31.8 (t), 32.25 (d), 32.34 (t), 32.4 (t), 32.7 
(d), 36.9 (t), 37.1 (t), 37.3 (t), 69.7 (t, JC-P = 6.9 Hz), 119.9 (d, J = 5.3 Hz), 125.1 (d), 129.6 









heptacosylphosphate (4.37): Alcohol 4.44 (70 mg, 0.10 mmol) was dissolved in EtOH-
EtOAc (3.0 mL, 1:1 v/v) and PtO2 (5 mg, 22 mol, 0.22 eq) was added. The resulting 
suspension was degassed with 3 vacuum-argon cycles and then saturated with H2  by 5 
vacuum-H2 cycles. After stirring for 60 h under an H2-atmosphere (1 bar), 1H-NMR showed 
  
 







complete conversion. The catalyst was removed by filtration over celite and the solution 
was neutralized with triethylamine. After concentration 4.44 (65 mg, 0.10 mmol, 
quantitative) was isolated as a yellow oil. 1H-NMR (CDCl3, 400 MHz)  = 0.78-0.90 (m, 
18H), 0.96-1.40 (m, 44H), 1.29 (t, J = 7.2 Hz, 9H), 1.59 (m, 2H),3.03 (q, J = 7.2 Hz, 6H), 
3.84 (m, 2H) ppm. 13C-NMR (CDCl3, 100.6 MHz)  = 0.9 (q), 8.8 (q), 14.0 (q), 19.6 (q), 
22.5 (t), 24.4 (t), 26.9 (t), 28.5 (t), 29.2 (t), 29.8 (t), 31.8 (t), 32.6 (d), 33.0 (t), 36.9 (t), 37.3 
(t), 45.3 (t), 65.3 (t) ppm. 31P-NMR (CDCl3, 161.6 MHz)  = 1.8 ppm. 
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